PATH: Form 990, tax year 2021
View the entire original 990 at ProPublica ↗
- Organization
- PATH (EIN 91-1157127)
- Tax period
- 2021-01-01 to 2021-12-31
- Filed
- 2022-11-14
- IRS object ID
- 202233189349301248
- Schema version
- 2021v4.2
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule I
- Schedule J
- Schedule M
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2022-11-14T07:51:46-06:00 | ReturnTs |
| Tax Period End | 2021-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 521392008 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | GELMAN ROSENBERG & FREEDMAN | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 4550 MONTGOMERY AVE SUITE 800N | AddressLine1Txt |
| City | BETHESDA | CityNm |
| State Abbreviation | MD | StateAbbreviationCd |
| ZIP | 208142930 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2021-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 911157127 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | PATH | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | PATH | BusinessNameControlTxt |
| Phone | 2062853500 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 2201 WESTLAKE AVENUE 200 | AddressLine1Txt |
| City | SEATTLE | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98121 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | KELLY PRIESTLEY | PersonNm |
| Person Title | CONTROLLER & PRIN. FIN. OFFICER | PersonTitleTxt |
| Phone | 2062853500 | PhoneNum |
| Signature | 2022-11-14 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
Signing Officer SigningOfficerGrp
Person Full Name PersonFullName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person First | KELLY | PersonFirstNm |
| Person Last | PRIESTLEY | PersonLastNm |
| Field | Value | IRS element (for citing) |
|---|---|---|
| SSN | 999009999 | SSN |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | RICHARD J LOCASTRO CPA | PreparerPersonNm |
| PTIN | P00288314 | PTIN |
| Phone | 3019519090 | PhoneNum |
Additional Filer Information AdditionalFilerInformation
Trusted Customer TrustedCustomerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Trusted Customer | 3 | TrustedCustomerCd |
| Authentication Assurance Level | AAL1 | AuthenticationAssuranceLevelCd |
| Identity Assurance Level | IAL1 | IdentityAssuranceLevelCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2021 | TaxYr |
| Build TS | 2022-09-23 18:48:47Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | KELLY PRIESTLEY | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 2201 WESTLAKE AVENUE 200 | AddressLine1Txt |
| City | SEATTLE | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98121 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $398,901,838 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.PATH.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 1981 | FormationYr |
| Legal Domicile State | WA | LegalDomicileStateCd |
| Activity Or Mission | SEE PART III, LINE 1. | ActivityOrMissionDesc |
| Voting Members Governing Body | 16 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 16 | VotingMembersIndependentCnt |
| Total Employee | 667 | TotalEmployeeCnt |
| Total Volunteers | 0 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $287,454,383 | PYContributionsGrantsAmt |
| CY Contributions Grants | $333,068,959 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $0 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $0 | CYProgramServiceRevenueAmt |
| PY Investment Income | $12,502,251 | PYInvestmentIncomeAmt |
| CY Investment Income | $9,205,357 | CYInvestmentIncomeAmt |
| PY Other Revenue | $1,030,112 | PYOtherRevenueAmt |
| CY Other Revenue | $843,270 | CYOtherRevenueAmt |
| PY Total Revenue | $300,986,746 | PYTotalRevenueAmt |
| CY Total Revenue | $343,117,586 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $67,994,827 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $75,961,955 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $132,096,396 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $135,407,327 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $5,667,202 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $92,968,260 | PYOtherExpensesAmt |
| CY Other Expenses | $123,975,347 | CYOtherExpensesAmt |
| PY Total Expenses | $293,059,483 | PYTotalExpensesAmt |
| CY Total Expenses | $335,344,629 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $7,927,263 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $7,772,957 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $283,556,203 | TotalAssetsBOYAmt |
| Total Assets EOY | $307,073,332 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $234,982,056 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $253,115,813 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $48,574,147 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $53,957,519 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | PATH'S MISSION IS TO ADVANCE HEALTH EQUITY THROUGH INNOVATION AND PARTNERSHIPS. (CONTINUED ON SCHEDULE O) | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $121,408,713 | ExpenseAmt |
| Grant | $32,739,259 | GrantAmt |
| Desc | THE PROGRAMS & INNOVATION DIVISION BRINGS DEEP TECHNICAL EXPERTISE AND A ROBUST, COLLABORATIVE, AND INTERDISCIPLINARY APPROACH TO SUPPORT PATH COUNTRY PROGRAMS AND PARTNERS IN ADVANCING HEALTH EQUITY. WE FOCUS ON GENERATING ANALYTICAL INSIGHTS, TRANSLATING THEM INTO ADVOCACY AND ACTION, ADVANCING INCLUSIVE AND SUSTAINABLE INNOVATION, AND STRENGTHENING WORKFORCE SKILLS AND RESOURCES THAT SUPPORT INTEGRATED AND RESILIENT HEALTH SYSTEMS. OUR WORK COVERS DIGITAL TRANSFORMATION, PRODUCT DEVELOPMENT, MARKET SHAPING, EPIDEMIC PREPAREDNESS AND RESPONSE, AND MORE.(CONTINUED ON SCHEDULE O)CENTER OF DIGITAL AND DATA EXCELLENCEPATH USES DIGITAL TECHNOLOGIES AND DATA-LED ACTION TO ADVANCE HEALTH EQUITY. IN 2021, PATH'S CENTER OF DIGITAL AND DATA EXCELLENCE CATALYZED COUNTRY-LED DIGITAL HEALTH TRANSFORMATION. FOR EXAMPLE, WORK CONTINUED ON THE DATA USE PARTNERSHIP, A BILL & MELINDA GATES FOUNDATION-FUNDED PROJECT WHERE PATH SUPPORTS THE GOVERNMENT OF TANZANIA TO IMPROVE ITS HEALTH INFORMATION SYSTEMS. THROUGH THIS PROJECT, THE GOVERNMENT ENDORSED A NEW HEALTH ENTERPRISE ARCHITECTURE, AN IMPORTANT STEP TO ENSURE ALIGNMENT OF THE COUNTRY'S DIGITAL SYSTEMS. IN ADDITION, THE PROJECT LAUNCHED AN IMPROVED E-LEARNING PLATFORM THAT STREAMLINES AND STANDARDIZES E-LEARNING MODULES TO MAKE IT EASIER TO TRACK HEALTH WORKER CREDENTIALS AND SCHOOL RECORDS.THE DATA USE ACCELERATION AND LEARNING PROJECT, ALSO FUNDED BY THE GATES FOUNDATION, CAPTURED LEARNINGS FROM FIVE COUNTRIES - BURKINA FASO, ETHIOPIA, MALAWI, SOUTH AFRICA, AND TANZANIA - TO DEVELOP A MODEL FOR DIGITAL TRANSFORMATION FOR DATA USE THAT BUILDS ON EXISTING FRAMEWORKS. THE INFORMATION WILL SUPPORT GOVERNMENTS, IMPLEMENTERS, POLICYMAKERS, AND FUNDERS AS THEY SHIFT THEIR FINANCING, GUIDANCE, AND PROGRAMMATIC APPROACHES TO IMPROVE THE USE OF DATA.BACKED BY A U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT (USAID) INVESTMENT OF UP TO $120 MILLION, DIGITAL SQUARE, A PATH-LED INITIATIVE, CONTINUED TO BRING DONORS AND PARTNERS TOGETHER TO IMPROVE HOW THE GLOBAL COMMUNITY DESIGNS, USES, AND PAYS FOR DIGITAL HEALTH TOOLS AND APPROACHES, WITH AN EMPHASIS ON COUNTRY-DRIVEN PRIORITIES.PATH, WITH U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) FUNDING, IS LEADING THE OVERALL HEALTH INFORMATION SYSTEM SUPPORT COMPONENT OF THE U.S. PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF (PEPFAR) TECHNICAL ASSISTANCE PLATFORM THAT PARTNERS WITH COUNTRIES TO SUPPORT THEM IN BUILDING LASTING DIGITAL HEALTH CAPACITY. IN 2021, THE TEAM RECEIVED APPROVAL FOR OUR SECOND-YEAR WORK PLAN AND BUDGET, ENABLING WORK TO BEGIN ON STRENGTHENING HEALTH SYSTEMS FOR HIV AND/OR COVID-19 IN COTE D'IVOIRE, ETHIOPIA, HAITI, KENYA, NAMIBIA, NIGERIA, RWANDA, VIETNAM, AND ZAMBIA.IN 2021, PATH SUPPORTED THE LAUNCH OF THE DIGITAL HEALTH APPLIED LEADERSHIP PROGRAM, A YEAR-LONG TRAINING THAT ENHANCES PARTICIPANTS' CAPACITY TO SUCCESSFULLY LEAD AND EXECUTE DIGITAL HEALTH PROGRAMS. DESIGNED WITH A COMPREHENSIVE LEADERSHIP CURRICULUM FOR A DIVERSE COHORT OF LEARNERS, THE PROGRAM CONSISTS OF CORE ONLINE COURSES, WORKSHOPS, INSTRUCTION FROM TUTORS, AND GUIDANCE FOR PLANNING AND DELIVERING A PROJECT TO BUILD DIGITAL HEALTH CAPACITY ACROSS PARTICIPATING COUNTRIES.PATH CONTINUED TO PARTICIPATE IN HIGH-LEVEL GLOBAL COALITIONS, INCLUDING TRANSFORM HEALTH, WHICH SUPPORTS THE DEVELOPMENT OF HEALTH DATA GOVERNANCE PRINCIPLES; THE LANCET/FINANCIAL TIMES JOINT COMMISSION, WHICH RELEASED ITS REPORT ON GOVERNING HEALTH FUTURES 2030; AND THE DIGITAL CONNECTED CARE COALITION.DIAGNOSTICSPATH'S DIAGNOSTICS PROGRAM AIMS TO ADVANCE AND INCREASE ACCESS TO HIGH-QUALITY AND APPROPRIATE DIAGNOSTICS THAT IMPROVE THE HEALTH OUTCOMES OF PEOPLE AND COMMUNITIES IN LOW-RESOURCE SETTINGS.IN 2021, OUR PIONEERING WORK SUPPORTED THE ADVANCEMENT OF AFFORDABLE, RELIABLE DIAGNOSTICS, PROTEINS, ANTIBODIES, AND TOOLS BY AIDING THE DEVELOPMENT, COMMERCIALIZATION, AND PROCUREMENT OF NEW TECHNOLOGIES; SECURING REGULATORY APPROVAL; CONDUCTING PERFORMANCE EVALUATIONS AND CLINICAL STUDIES TO INFORM PATIENT CARE; AND PUBLISHING 18 PEER-REVIEWED ARTICLES.IN RESPONSE TO THE GLOBAL COVID-19 PANDEMIC, WE SUPPORTED THE DEVELOPMENT AND VALIDATION OF DIAGNOSTIC TOOLS, TECHNOLOGIES, AND SOLUTIONS SUITABLE FOR USE IN LOW- AND MIDDLE-INCOME COUNTRIES (LMICS). THIS INCLUDED DEVELOPING MULTIPLE PUBLICLY AVAILABLE INTERACTIVE COVID-19 DIAGNOSTIC DASHBOARDS TO SUPPORT DATA-DRIVEN PRODUCT SELECTION AND PROCUREMENT DECISIONS; CREATING A COVID-19 SAMPLE REPOSITORY TO SUPPORT DEVELOPERS IN ACCESSING CLINICAL SAMPLES FOR RESEARCH AND DEVELOPMENT; ENSURING THE QUALITY OF COVID-19 RAPID DIAGNOSTIC TESTS WITH A BENCHMARKING PANEL THAT ENABLES UNBIASED, COMPARATIVE EVALUATIONS BETWEEN COVID-19 TESTS; SUPPORTING THE NATIONAL RESPONSE IN BRAZIL, INDONESIA, MALAWI, NEPAL, AND PAKISTAN TO DETECT AND QUANTIFY THE PRESENCE OF SARS-COV-2 IN WASTEWATER; AND CONDUCTING CLINICAL AND OPERATIONAL STUDIES TO ENSURE THAT COVID-19 POINT-OF-CARE TESTS ARE AN EFFECTIVE MEANS OF COMBATTING COVID-19 IN SETTINGS WHERE LABORATORY RESULTS ARE DELAYED OR UNAVAILABLE.IN MAY 2021, THE SD BIOSENSOR STANDARD G6PD TEST RECEIVED REGULATORY APPROVAL FROM THE AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION (TGA). PATH HELPED GUIDE THE TEST THROUGH PRODUCT DEVELOPMENT AND CLINICAL EVIDENCE GENERATION FOR SUBMISSION TO THE TGA. THIS IS THE FIRST POINT-OF-CARE TEST FOR GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) DEFICIENCY THAT CAN SUPPORT SAFE ACCESS TO THE CURRENTLY AVAILABLE DRUGS FOR PLASMODIUM VIVAX MALARIA.IN COLLABORATION WITH THE UNIVERSITY OF QUEENSLAND'S PROTEIN EXPRESSION FACILITY, PATH ADVANCED THE COMMERCIALIZATION OF HIGHLY SPECIFIC AND SENSITIVE MALARIA ANTIGEN REAGENTS FOR IMMUNOLOGICAL TESTS. THESE NEWLY AVAILABLE CUSTOM PROTEINS WILL FACILITATE DEVELOPMENT AND PERFORMANCE BENCHMARKING OF RAPID, ACCURATE, SPECIES-SPECIFIC MALARIA DIAGNOSTICS. THE DIAGNOSTICS TEAM CONTINUED TO MANAGE A COMMUNITY OF PRACTICE FOR G6PD OPERATIONAL RESEARCH AND HOSTED SIX INFORMATION-SHARING WEBINARS.IN COLLABORATION WITH THE U.K. NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROLS, PATH WORKED TO DEVELOP AND RELEASE 14 HIGH-QUALITY AND AFFORDABLE MONOCLONAL ANTIBODIES TO SUPPORT DEVELOPMENT OF PNEUMOCOCCAL VACCINES THAT ARE LOW-COST, SEROTYPE-SPECIFIC, AND TAILORED FOR USE BY VACCINE DEVELOPERS AND RESEARCHERS IN LMICS.MEDICAL DEVICES AND HEALTH TECHNOLOGIES THE MEDICAL DEVICES AND HEALTH TECHNOLOGIES PROGRAM IS PATH'S PRODUCT DEVELOPMENT ARM. THE PROGRAM WORKS WITH PUBLIC- AND PRIVATE-SECTOR PARTNERS AROUND THE WORLD TO DEVELOP, TEST, INTRODUCE, AND SCALE UP AFFORDABLE INNOVATIONS TO IMPROVE THE HEALTH OF PEOPLE IN LMICS. FOR EXAMPLE, IN COLLABORATION WITH LOCAL STAKEHOLDERS AND RESEARCHERS, WE DEVELOP FIT-FOR-PURPOSE HEALTH TECHNOLOGIES SUCH AS THE ELLAVI UTERINE BALLOON TAMPONADE (UBT), A LIFESAVING INTERVENTION FOR POSTPARTUM HEMORRHAGE. IN 2021, THE ELLAVI UBT'S AVAILABILITY GREW TO 16 COUNTRIES. THE CAYA DIAPHRAGM, ANOTHER PATH-DEVELOPED MEDICAL DEVICE, ACHIEVED REGULATORY APPROVAL IN 7 LATIN AMERICAN COUNTRIES, BRINGING THE GLOBAL TOTAL TO 39 COUNTRIES WHERE THE DEVICE IS NOW AVAILABLE.PATH CONTINUED TO SUPPORT INCLUSIVE INNOVATION, HIRING ADDITIONAL DESIGN AND INNOVATION SPECIALISTS IN AFRICA, WHICH ALLOWED THE LIVING LABS INITIATIVE TO CO-CREATE WITH APPROXIMATELY 1,000 FRONTLINE HEALTH WORKERS AND COMMUNITY MEMBERS. THE PATH MICROARRAY PATCH CENTER OF EXCELLENCE CONTINUED OUR CROSS-SECTOR WORK TO ADVANCE THIS NEEDLE-FREE DELIVERY TECHNOLOGY PLATFORM FOR MEASLES, RUBELLA, AND COVID-19 VACCINES.FINALLY, WE CONVENED A GLOBAL SYRINGE MANUFACTURER WORKSHOP AND PRODUCED AN AUTODISABLE SYRINGE GAP ANALYSIS MODEL TO INFORM GLOBAL STAKEHOLDERS AND U.S. DECISION-MAKERS. WE ALSO PRODUCED AND SHARED GLOBAL COLD CHAIN MODELING DATA FOR COVID-19 VACCINES ACROSS 92 ADVANCED MARKET COMMITMENT COUNTRIES. TO ADDRESS THE URGENT NEED FOR A COVID-19 VACCINE THAT IS THERMOSTABLE AND NEEDLE-FREE, THE FORMULATION TEAM SUBMITTED A PATENT APPLICATION FOR A FREEZE-DRIED FORMULATION OF AN MRNA VACCINE SUITABLE FOR ORAL AND PARENTERAL ADMINISTRATION.MARKET DYNAMICSPATH'S MARKET DYNAMICS PROGRAM WORKS TO INCREASE EQUITABLE ACCESS TO HEALTH PRODUCTS AND SERVICES BY DIAGNOSING THE ROOT CAUSES OF MARKET FAILURES, DESIGNING APPROPRIATE SOLUTIONS, AND DEVELOPING SUSTAINABLE AND INCLUSIVE HEALTH MARKETS. THIS WORK COMPLEMENTS PATH'S OTHER EFFORTS, SUCH AS PRODUCT DEVELOPMENT/INTRODUCTION AND HEALTH SYSTEMS STRENGTHENING, AND IS DONE IN CLOSE COLLABORATION WITH NATIONAL MINISTRIES OF HEALTH, GLOBAL AGENCIES, COMMERCIAL PARTNERS, AND PATH'S COUNTRY PROGRAMS. IN 2021, OUR LARGEST AREAS OF WORK WERE: | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $100,080,790 | ExpenseAmt |
| Grant | $33,744,940 | GrantAmt |
| Desc | ESSENTIAL MEDICINES: PATH'S ESSENTIAL MEDICINES DIVISION DEVELOPS AND DELIVERS LIFESAVING VACCINES AND DRUGS FOR WOMEN, CHILDREN, AND COMMUNITIES AROUND THE GLOBE.(CONTINUED ON SCHEDULE O)CENTER FOR VACCINE INNOVATION AND ACCESSPATH'S CENTER FOR VACCINE INNOVATION AND ACCESS ALIGNS EXPERTISE ACROSS EVERY STAGE OF VACCINE RESEARCH, DEVELOPMENT, AND INTRODUCTION TO MAKE VACCINES AVAILABLE TO MORE COMMUNITIES, PARTICULARLY IN LMICS. OUR PORTFOLIO INCLUDES MORE THAN TWO DOZEN VACCINE PRODUCTS IN DEVELOPMENT OR ALREADY IN USE, WITH AN EMPHASIS ON THE LEADING INFECTIOUS CAUSES OF CHILD DEATH AND DISEASE WORLDWIDE.IN 2021, PATH CONTINUED TO SUPPORT THE GLOBAL COVID-19 RESPONSE BY PROVIDING EXPERTISE TO THE COVAX FACILITY, SUPPORTING VACCINE SUPPLY CHAIN NETWORKS, PROVIDING TECHNICAL ASSISTANCE AND TRAINING TO VACCINE MANUFACTURERS, STRENGTHENING CLINICAL RESEARCH CENTER AND COUNTRY DELIVERY READINESS, AND TRAINING PHARMACISTS AS VACCINATORS IN GHANA. WE ALSO SUPPORTED THE MRNA VACCINE TECHNOLOGY HUB IN SOUTH AFRICA AND PROVIDED COORDINATION AND TECHNICAL ASSISTANCE FOR A CONSORTIUM DEVELOPING AN EGG-BASED COVID-19 VACCINE FOR PRODUCTION IN BRAZIL, THAILAND, VIETNAM, AND OTHER LMICS. ADDITIONALLY, PATH GUEST EDITED A SPECIAL ISSUE OF VACCINE INSIGHTS ON COVID-19.IN ONGOING EFFORTS TO FACILITATE LOCAL VACCINE PRODUCTION, PATH SUPPORTED VIETNAM-BASED MANUFACTURER POLYVAC TO ESTABLISH A SYSTEM FOR CONDUCTING POST-LICENSURE VACCINE SAFETY SURVEILLANCE AND DATA ANALYSIS. THIS NEW SYSTEM ENSURES POLYVAC'S COMPLIANCE WITH LOCAL AND GLOBAL REGULATORY REQUIREMENTS. PATH ALSO SUPPORTED CHINESE VACCINE MANUFACTURERS TO READY LOCALLY MADE VACCINES FOR THE GLOBAL MARKET, THEREBY INCREASING AVAILABLE INTERVENTIONS AND POTENTIALLY MAKING VACCINES MORE ACCESSIBLE FOR LMICS. WE HELPED LAUNCH A PHASE 3 CLINICAL STUDY IN KENYA OF A YELLOW FEVER VACCINE FROM BEIJING INSTITUTE OF BIOLOGICAL PRODUCTS. DATA FROM THE STUDY WILL SUPPORT AN APPLICATION FOR WHO PREQUALIFICATION (PQ), A KEY STEP FOR GLOBAL AVAILABILITY. WE PROVIDED TECHNICAL ASSISTANCE TO SEVERAL OTHER MANUFACTURERS PREPARING FOR WHO PQ SUBMISSION OR INSPECTION; THUS IN 2021, SINOVAC BIOTECH LTD'S COVID-19 VACCINE, CORONAVAC, RECEIVED EMERGENCY USE LISTING, AND XIAMEN INNOVAX BIOTECH'S HPV VACCINE, CECOLIN, RECEIVED WHO PQ. PATH CONTINUED TO PROVIDE TECHNICAL SUPPORT TO POLIO VACCINE MANUFACTURERS AND ADVANCE RESEARCH ON NEW INACTIVATED POLIO VACCINE AND ORAL POLIO VACCINE CANDIDATES. BASED ON THE REAL-WORLD PERFORMANCE OF A NOVEL ORAL POLIO VACCINE AGAINST TYPE 2 POLIOVIRUS (NOPV2), THE WHO STRATEGIC ADVISORY GROUP OF EXPERTS ON IMMUNIZATION (SAGE) ENDORSED WIDER USE OF NOPV2 UNDER THE EMERGENCY USE LISTING. PATH ALSO LAUNCHED A PHASE 3 STUDY OF NOPV2 AND A PHASE 1 STUDY OF NOPV1.THROUGHOUT THE YEAR, PATH AND OUR PARTNERS EXPANDED COVERAGE OF JAPANESE ENCEPHALITIS (JE) VACCINATION AND DEVELOPED AND DISSEMINATED EVIDENCE TO SUPPORT JE VACCINE DECISION-MAKING. PATH LAUNCHED A NEW STUDY ON THE COST OF ILLNESS FOR JE AND ITS LONG-TERM CONSEQUENCES IN BANGLADESH, LAOS, AND VIETNAM. WE ALSO WORKED CLOSELY WITH THE GOVERNMENT OF BANGLADESH AND LOCAL PARTNERS TO INFORM THE COUNTRY'S JE VACCINATION DECISION-MAKING, WITH AN APPLICATION TO GAVI, THE VACCINE ALLIANCE (GAVI) EXPECTED IN 2022.ALSO IN 2021, WE CONTINUED A PIVOTAL PHASE 3 STUDY OF A POLYVALENT MENINGOCOCCAL MENINGITIS CONJUGATE VACCINE. THIS VACCINE, DEVELOPED BY SERUM INSTITUTE OF INDIA PVT. LTD., BUILDS ON THE SUCCESS OF MENAFRIVAC, A GROUNDBREAKING VACCINE AGAINST SEROGROUP A MENINGOCOCCAL MENINGITIS THAT WAS DEVELOPED THROUGH AN EARLIER PATH PARTNERSHIP. THE POLYVALENT VACCINE TARGETS SEROGROUPS A, C, W, X, AND Y. AS THE FIRST VACCINE TO TARGET SEROGROUP X, THE VACCINE HAS THE POTENTIAL TO ELIMINATE MENINGOCOCCAL MENINGITIS EPIDEMICS FROM AFRICA'S "MENINGITIS BELT" REGION. WE CONTRIBUTED TECHNICAL AND STRATEGIC EXPERTISE TO THE GLOBAL DEFEATING MENINGITIS BY 2030 INITIATIVE AND SUPPORTED THE WHO CELEBRATION AND LAUNCH OF DEFEATING MENINGITIS BY 2030: A GLOBAL ROAD MAP.PATH ACCELERATED THE DEVELOPMENT AND INTRODUCTION OF A WIDE VARIETY OF MALARIA VACCINE CANDIDATES AND APPROACHES. WE CONTINUED TO WORK WITH WHO; THE MINISTRIES OF HEALTH IN GHANA, KENYA, AND MALAWI; AND OTHER PARTNERS TO INTRODUCE THE WORLD'S FIRST MALARIA VACCINE, KNOWN AS RTS,S, IN SELECTED AREAS OF THOSE COUNTRIES. IN 2021, THE VACCINE RECEIVED A RECOMMENDATION FROM WHO FOR BROAD USE TO CURB PLASMODIUM FALCIPARUM MALARIA IN CHILDREN LIVING IN MODERATE-TO-HIGH MALARIA TRANSMISSION AREAS. WE CONTINUED TO ADVANCE RESEARCH INTO WHETHER REDUCING THE DOSE LEVEL OF RTS,S AND DELAYING THE ADMINISTRATION OF DOSES HAS THE POTENTIAL TO STRETCH LIMITED VACCINE SUPPLIES. WE ALSO RESEARCHED USE OF THE VACCINE TO AVERT HIGHLY SEASONAL MALARIA ALONGSIDE SEASONAL MALARIA CHEMOPREVENTION. WE CONTINUED WORK TO IDENTIFY IMMUNE CORRELATES OF PROTECTION AND STUDY THE USE OF MONOCLONAL ANTIBODIES TO PREVENT MALARIA, AND WE CONTINUED WORK ON A FIVE-YEAR CONTRACT FROM USAID TO ADVANCE PRE-ERYTHROCYTIC, BLOOD-STAGE, AND COMBINATION MALARIA VACCINE APPROACHES.THE DEFEAT DIARRHEAL DISEASE (DEFEATDD) INITIATIVE CONTINUED ITS ROLE AS A DIGITAL HUB FOR INFORMATION ON PREVENTING AND TREATING CHILDHOOD DIARRHEAL DISEASE, THE SECOND-LEADING CAUSE OF DEATH AMONG CHILDREN IN LMICS. A MAJOR FOCUS OF 2021 WAS HIGHLIGHTING CLIMATE CHANGE AND GENDER INEQUITY AS MAJOR DRIVERS OF CHILD HEALTH OUTCOMES.TO REDUCE THE BURDEN OF ROTAVIRUS, A MAJOR CAUSE OF SEVERE DIARRHEA, PATH CONTINUED CLINICAL DEVELOPMENT OF AN INJECTABLE NONREPLICATING ROTAVIRUS VACCINE CANDIDATE WITH THE START OF A PHASE 3 EFFICACY STUDY AT THREE CLINICAL SITES IN AFRICA. PATH ALSO BEGAN A PHASE 2 STUDY WITH THIS CANDIDATE IN SOUTH AFRICA TO EXAMINE IMMUNE RESPONSES TO DIFFERENT COMBINATIONS OF ORAL AND INJECTED ROTAVIRUS VACCINES. IN ADDITION, PATH CONTINUED A CASE-CONTROL STUDY IN INDIA TO EVALUATE THE EFFECTIVENESS OF SERUM INSTITUTE OF INDIA PVT. LTD.'S LICENSED ROTAVIRUS VACCINE, ROTASIIL. PATH CONTINUED TO SUPPORT CLINICAL TRIALS AND RESEARCH ON VACCINE CANDIDATES THAT MAY PROVIDE PROTECTION AGAINST ENTEROTOXIGENIC ESCHERICHIA COLI (ETEC) AND SHIGELLA, THE LEADING BACTERIAL CAUSES OF DIARRHEAL ILLNESS. CURRENTLY, THERE ARE NO LICENSED VACCINES AGAINST EITHER PATHOGEN. WE COMPLETED FURTHER ANALYSIS OF RESULTS FROM A PHASE 2B EFFICACY STUDY OF AN ORAL ETEC VACCINE CANDIDATE (ETVAX) IN FINNISH TRAVELERS TO BENIN, WHICH SHOWED ETVAX VACCINATION REDUCED THE NEED FOR ANTIBIOTICS. IN ADDITION, WE COMPLETED IN-DEPTH EXPLORATORY IMMUNOLOGY ANALYSES OF A NOVEL, INJECTABLE SUBUNIT SHIGELLA VACCINE CANDIDATE USING SAMPLES FROM A RECENT PHASE 1 STUDY SUGGESTING EFFECTIVE IMMUNIZATION MAY BE POSSIBLE WITH A SINGLE DOSE.PATH CONTINUED TO ADVANCE PRECLINICAL DEVELOPMENT OF A VACCINE AGAINST GROUP B STREPTOCOCCUS, A LEADING CAUSE OF BACTERIAL SEPSIS AND MENINGITIS IN YOUNG INFANTS WORLDWIDE, AND AGAINST PNEUMOCOCCAL DISEASE, A TOP CAUSE OF DEADLY CHILDHOOD PNEUMONIA. WE SUPPORTED INVENTPRISE AS IT WORKS TO DEVELOP MULTIVALENT CONJUGATE VACCINES FOR BOTH DISEASES THAT WILL BE AFFORDABLE FOR LMICS.AS PART OF THE TYPHOID VACCINE ACCELERATION CONSORTIUM, PATH WORKED TO ADVANCE TYPHOID CONJUGATE VACCINE (TCV) INTRODUCTION IN GAVI-ELIGIBLE COUNTRIES: IN MALAWI AND NEPAL, WE CONTINUED TO SUPPORT EACH GOVERNMENT IN PLANNING FOR TCV INTRODUCTION; IN PAKISTAN, WE SUPPORTED THE GOVERNMENT IN PLANNING FOR THE CONCLUSION OF THE NATIONAL ROLLOUT; IN LIBERIA AND ZIMBABWE, WE WRAPPED UP OUR SUPPORT AFTER SUCCESSFUL TCV INTRODUCTION CAMPAIGNS; AND IN ADDITIONAL COUNTRIES, WE INITIATED DISCUSSIONS TO SUPPORT DECISION-MAKING. WE CONTINUED TO SHARE NEW DATA AND SERVE AS A HUB FOR TYPHOID INFORMATION, RAISING AWARENESS ON TYPHOID DISEASE AND PREVENTION THROUGH AN INTEGRATED APPROACH THAT INCLUDES VACCINES. TO PREVENT CERVICAL CANCER, PATH CONTINUED TO COORDINATE A CONSORTIUM OF NINE INDEPENDENT RESEARCH INSTITUTIONS TO COLLATE, ANALYZE, AND DISSEMINATE EVIDENCE ON SINGLE-DOSE HPV VACCINATION. THIS INCLUDED SYNTHESIZING NEWLY AVAILABLE, CRITICAL CLINICAL TRIAL DATA TO PREPARE FOR AND PRESENT EVIDENCE TO WHO'S SAGE. A SINGLE-DOSE SCHEDULE WOULD HELP ALLEVIATE COUNTRIES' FINANCIAL, LOGISTICAL, OR OTHER BARRIERS TO HPV VACCINE INTRODUCTION. PATH ALSO SPONSORED A PHASE 3 STUDY OF A LICENSED HPV VACCINE IN GHANA AND BANGLADESH TO GENERATE EVIDENCE IN LMICS AND ON EXTENDED DOSING SCHEDULES, AND CONTINUED DATA COLLECTION FOR AN HPV COST-OF-DELIVERY STUDY IN SIX COUNTRIES WITH HPV VACCINATION PROGRAMS. | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $37,745,269 | ExpenseAmt |
| Grant | $4,420,524 | GrantAmt |
| Desc | AFRICA REGION: PATH'S WORK IN AFRICA INTERSECTS VIRTUALLY EVERY PATH GLOBAL PROGRAM, FROM ADVOCACY AND PUBLIC POLICY TO SEXUAL AND REPRODUCTIVE HEALTH. WE HAVE COUNTRY OFFICES IN SEVEN SUB-SAHARAN NATIONS SPANNING CENTRAL, EASTERN, SOUTHERN, AND WESTERN AFRICA: THE DRC, ETHIOPIA, KENYA, SENEGAL, TANZANIA, UGANDA, AND ZAMBIA - WITH PROJECT OFFICES IN SEVEN MORE. HIGHLIGHTS FROM OUR COUNTRY OFFICES INCLUDE:(CONTINUED ON SCHEDULE O)DRCIN 2021, PATH'S ENGAGEMENT IN THE DRC FOCUSED ON HIV/AIDS, VACCINATION (COVID-19 AND POLIO), AND HEALTH SYSTEM STRENGTHENING. FOR EXAMPLE, THE USAID INTEGRATED HIV/AIDS PROJECT, WHICH PATH LEADS IN HAUT-KATANGA PROVINCE (IHAP-HK), ACHIEVED THE INTERNATIONAL GOLD STANDARD RATE OF 95% UNDETECTABLE VIRAL LOAD AMONG A COHORT OF 45,000. PATH ALSO SUPPORTED THE COVID-19 RESPONSE, INCLUDING HOSTING THE PRESIDENTIAL COVID-19 TASK FORCE IN OUR KINSHASA OFFICE, CONDUCTING THE FIRST DRC NATIONWIDE OXYGEN AVAILABILITY ASSESSMENT, AND MONITORING COVID-19 VACCINATION (THE LATTER VIA THE USAID M-RITE PROJECT). PATH SUPPORTED THE DRC PRESIDENT'S OFFICE FOR THE SECOND PRESIDENTIAL IMMUNIZATION AND POLIO ERADICATION FORUM. TO ACCELERATE TWO HIGH-PRIORITY INITIATIVES - THE DIGITAL TRANSFORMATION OF THE COUNTRY'S HEALTH SECTOR AND UNIVERSAL HEALTH COVERAGE - THE MOH, WITH SUPPORT FROM THE DIGITAL SQUARE TEAM WITHIN PATH, LAUNCHED AN INVESTMENT ROAD MAP WITH MORE THAN 60 INSTITUTIONS PARTICIPATING IN PRIORITIZING CATALYTIC INVESTMENTS.ETHIOPIAWITH FUNDING FROM GAVI THROUGH THE TARGETED COUNTRY ASSISTANCE (TCA) PROJECT, PATH SUPPORTED THE AFAR REGION TO PILOT AND IMPLEMENT CATCH-UP IMMUNIZATION IN TWO CONFLICT-AFFECTED AREAS. PATH ALSO SUPPORTED THE MOH TO IMPLEMENT A VACCINATION STRATEGY DESIGNED SPECIFICALLY FOR COVID-19 VACCINE AND HPV VACCINE, CONDUCTING AN INTEGRATED VACCINATION CAMPAIGN NATIONWIDE FOR TWO COHORTS OF ADOLESCENT GIRLS AND YOUNG WOMEN. IN CLOSE COLLABORATION WITH THE MOH, PATH DESIGNED AND WAS AWARDED A PROJECT FROM BIG WIN PHILANTHROPY TO REVAMP AND RESTORE MATERNAL AND CHILD HEALTH PROGRAMS IN CONFLICT-AFFECTED AREAS, WITH A FOCUS ON EARLY CHILDHOOD DEVELOPMENT AND CAREGIVER HEALTH.KENYAPATH'S NONCOMMUNICABLE DISEASES (NCD) TEAM PARTNERED WITH THE KENYA GOVERNMENT TO EVALUATE THE NATIONAL NCD STRATEGY 2015-2020 TO INFORM THE DESIGN AND DEVELOPMENT OF THE NCD STRATEGY 2021-2026. FOLLOWING LAUNCH OF THE STRATEGY IN JULY 2021, PATH SUPPORTED DISSEMINATION TO OUR FOCAL COUNTIES. PATH IS PRIME ON THE PEPFAR-FUNDED USAID NURU YA MTOTO PROJECT, WITH A FIVE-YEAR (2021-2026) BUDGET OF MORE THAN $44 MILLION. THROUGH THIS PROJECT, PATH LEADS A CONSORTIUM THAT PROVIDES HIV SERVICES TO YOUNG PEOPLE IN HOMA BAY, KISII, AND MIGORI COUNTIES. THROUGH THE DREAMS INITIATIVE, WE CONTINUED TO SUPPORT HIV PREVENTION FOR ADOLESCENT GIRLS AND YOUNG WOMEN. WORKING AS A SUBPARTNER, PATH ALSO SUPPORTED BORESHA JAMII, A PEPFAR-FUNDED USAID PROJECT TO INCREASE ACCESS TO AND DEMAND FOR HIGH-QUALITY TB/HIV PREVENTION, CARE, AND TREATMENT.RTS,S, THE WORLD'S FIRST MALARIA VACCINE, WAS DEVELOPED BY GSK OVER MORE THAN 30 YEARS AND IN PARTNERSHIP WITH PATH SINCE 2001. IN OCTOBER 2021, WHO RECOMMENDED EXPANDING USE OF THE VACCINE ACROSS THE AFRICAN CONTINENT. WITH PATH SUPPORT, KENYA, ONE OF THE FIRST COUNTRIES TO GAIN REGULATORY APPROVAL FOR RTS,S, EMBARKED ON A PHASED INTRODUCTION AND EVALUATION TO LEARN HOW BEST TO IMPLEMENT THE VACCINE WITHIN THE CONTEXT OF ROUTINE IMMUNIZATION.THE PATH KENYA LIVING LABS TEAM IN 2021 FINALIZED THE DESIGN AND PILOT TESTING OF A PROTOTYPE DIGITAL TOOL TO SUPPORT SCHEDULING FOR BOTH IMMUNIZATION AND PHC SERVICES. THE TOOL COMPLEMENTS AN IMMUNIZATION DASHBOARD DEVELOPED BY THE LIVING LABS TEAM TO TRACK PERFORMANCE ON KEY INDICATORS ACROSS KENYA'S COUNTIES, SUBCOUNTIES, AND FACILITIES. KENYA IS ONE OF SEVERAL COUNTRIES RECEIVING SUPPORT THROUGH THE COVID-19 RESPIRATORY CARE RESPONSE COORDINATION PROJECT, A CONSORTIUM FUNDED BY THE BILL & MELINDA GATES FOUNDATION. IN 2021, THE CONSORTIUM, LED BY PATH, PROCURED AND INSTALLED RESPIRATORY CARE EQUIPMENT AT 23 HIGH-VOLUME FACILITIES AND ENSURED THE REPAIR/INSTALLATION OF FIVE OXYGEN GENERATION PLANTS AT TERTIARY/REFERRAL HEALTH FACILITIES. ADDITIONALLY, PATH SUPPORTED KENYAN COUNTIES IN CONDUCTING CAPACITY-BUILDING AND SUPPORTIVE SUPERVISION UNDER THE M-RITE PROJECT, WHICH FOCUSES ON IMMUNIZATION.SENEGALPATH PROVIDED TECHNICAL ASSISTANCE AND LOGISTICAL SUPPORT TO THE MOH IN ROLLING OUT THE 3RD EDITION OF THE INTEGRATED DISEASE SURVEILLANCE AND RESPONSE SYSTEM, A KEY TOOL IN IDENTIFYING, MANAGING, AND MITIGATING INFECTIOUS DISEASE OUTBREAKS. RELATED, PATH PROVIDED TECHNICAL ASSISTANCE TO THE DIRECTORATE OF LABORATORIES AND THE MOH IN DEVELOPING AND VALIDATING NATIONAL STANDARD OPERATING PROCEDURES FOR DETECTION AND SURVEILLANCE OF ANTIMICROBIAL RESISTANCE (AMR).PATH SUPPORTED THE GOVERNMENT IN VARIOUS ASPECTS OF ITS COVID-19 RESPONSE, INCLUDING PROCUREMENT OF EQUIPMENT AND REAGENTS FOR DIAGNOSTIC TESTS AS WELL AS INTENSIVE CARE EQUIPMENT FOR TREATMENT OF SEVERE CASES. AT THE COMMUNITY LEVEL, PATH WORKED TO STIMULATE DEMAND FOR COVID-19 VACCINATION.IN 2021, THE TOOLS FOR INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS (TIMCI) PROJECT LAUNCHED IN SENEGAL, AND THE TRAINING, SUPERVISION, AND COMMUNITY ENGAGEMENT PHASE BEGAN WITH IMPLEMENTATION AT FOUR INTERVENTION SITES. TIMCI (WITH PATH AS LEAD PARTNER) SUPPORTED THE MOH TO REVISE THE COUNTRY'S INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS GUIDELINES WITH THE SPECIFIC OBJECTIVE OF INCLUDING PULSE OXIMETRY AND OXYGEN THERAPY INDICATIONS. AS PATH'S WESTERN AFRICA HUB, PATH SENEGAL SUPPORTED THE MOH OF GUINEA, A NEIGHBORING COUNTRY, IN INTEGRATING ALL VIRAL HEMORRHAGIC FEVERS, INCLUDING EBOLA, INTO ITS NATIONAL SURVEILLANCE EARLY WARNING SYSTEM. PATH ALSO PROVIDED TECHNICAL ASSISTANCE TO THE GOVERNMENT OF MALI IN THE DIGITALIZATION OF COVID-19 VACCINATION DATA.TANZANIAIN 2021, THE DATA USE PARTNERSHIP, A COLLABORATION BETWEEN PATH AND THE GOVERNMENT OF TANZANIA, LAUNCHED THE AFYA SUPPORTIVE SUPERVISION PLAN TO IMPLEMENT A DIGITAL SYSTEM FOR DATA COLLECTION IN HEALTH FACILITIES. THE PLAN SUPPLIED 900 TABLETS TO NATIONAL- AND REGIONAL-LEVEL USERS, WITH PATH LEVERAGING OUR EXPERTISE TO SUPPORT TRAININGS ON THE EQUIPMENT AND SOFTWARE.ALSO IN TANZANIA, THE INFECTIOUS DISEASE DETECTION AND SURVEILLANCE (IDDS) PROJECT OPERATIONALIZED A NATIONAL AMR SURVEILLANCE FRAMEWORK. HEALTH WORKERS IN THE COUNTRY CAN NOW SUBMIT HIGH-QUALITY AMR DATA PRODUCED THROUGH THIS FRAMEWORK TO THE NATIONAL DATABASE AND THE GLOBAL AMR SURVEILLANCE SYSTEM.IN COLLABORATION WITH THE MOH, PATH LAUNCHED THE TIMCI PROJECT IN THREE DISTRICTS. WORK IN 2021 INCLUDED DEVELOPING, DEPLOYING, AND SUPPORTING IMPLEMENTATION OF AN ELECTRONIC CLINICAL DECISION-SUPPORT ALGORITHM. PATH'S DIGITAL SQUARE INITIATIVE SUPPORTED THE MOH IN IMPLEMENTING A STANDARDS-BASED NATIONAL HEALTH INFORMATION EXCHANGE PLATFORM THAT BY CLOSE OF 2021 ALLOWED FOR EXCHANGE OF DATA BETWEEN 13 DISPARATE HEALTH INFORMATION SYSTEMS. THROUGH GAVI/TCA, PATH SUPPORTED THE MOH TO TRANSITION FROM A TRADITIONAL, PAPER-BASED SYSTEM FOR IMMUNIZATION TRACKING TO FULL ELECTRONIC DATA COLLECTION AND MANAGEMENT IN MORE THAN 600 PHC FACILITIES. SEPARATELY, PATH SUPPORTED THE MOH TO DEVELOP A RESPIRATORY CARE EQUIPMENT BASELINE ASSESSMENT TOOL, MEDICAL OXYGEN TRAINING MANUAL, AND SCALE-UP PLAN.IN LATE 2021, THE HEALTHY HEART AFRICA PROJECT BEGAN IN TANZANIA WITH THE SIGNING OF A MEMORANDUM OF UNDERSTANDING BETWEEN THE MOH AND ASTRAZENECA, AFTER WHICH PATH CONDUCTED A STAKEHOLDER WORKSHOP TO INTRODUCE THE PROJECT AND ENSURE GOVERNMENT COMMITMENT AND ACCOUNTABILITY. UGANDAIN 2021, PATH'S ADVOCACY AND PUBLIC POLICY TEAM IN UGANDA INFLUENCED THE INTRODUCTION OF A SUPPLEMENTARY BUDGET FOR COVID-19 VACCINATION AND ENSURED BUDGET INCREASES FROM PREVIOUS YEARS FOR ROUTINE IMMUNIZATION AND PHC WERE MAINTAINED DESPITE BUDGET SHORTFALLS AT THE NATIONAL LEVEL. PATH SUCCESSFULLY ADVOCATED FOR THE PASSAGE OF A NATIONAL HEALTH INSURANCE SCHEME AND HELPED DEVELOP A UNIVERSAL HEALTH COVERAGE ROAD MAP AND COMMUNITY HEALTH EXTENSION WORKERS STRATEGY IN PILOT DISTRICTS. OUR TEAM ADVOCATED FOR INTEGRATION OF THE ADDIS DECLARATION ON IMMUNIZATION COMMITMENTS INTO EXPANDED PROGRAM ON IMMUNIZATION WORK PLANS BY CREATING AND DISSEMINATING A SCORECARD TOOL TO SERVE AS AN ACCOUNTABILITY FRAMEWORK. PATH IN UGANDA ALSO ADVOCATED FOR PRIORITIZATION OF ROUTINE IMMUNIZATION TO PREVENT BACKSLIDING DURING COVID-19, WITH A FOCUS ON CATCH-UP CAMPAIGNS SUCH AS A NATIONAL POLIO IMMUNIZATION CAMPAIGN. PATH ALSO SUPPORTED THE MOH TO DISSEMINATE GUIDELINES ON THE CONTINUITY OF ESSENTIAL HEALTH SERVICES DURING COVID-19 AT THE SUBNATIONAL LEVEL, REACHING MORE THAN 400 CHAMPIONS AND HEALTH CARE WORKERS THROUGH TECHNICAL WORKSHOPS AND TRAININGS. | Desc |
Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $41,899,328 | ExpenseAmt |
| Grant | $5,057,232 | GrantAmt |
| Desc | ADVOCACY AND PUBLIC POLICYPATH'S ADVOCACY AND PUBLIC POLICY TEAM WORKS IN THE UNITED STATES, IN AFRICA (DRC, KENYA, SOUTH AFRICA, AND UGANDA), AND AT THE GLOBAL LEVEL WITH MULTILATERAL AGENCIES. WE PARTNER WITH POLICYMAKERS TO HELP THEM UNDERSTAND ISSUES AND MOTIVATE THEM TO COMMIT FUNDING, CRAFT POLICIES, AND SPONSOR INITIATIVES TO STRENGTHEN GLOBAL HEALTH. AS A 501(3)C ORGANIZATION, PATH DOES NOT INFLUENCE THE OUTCOMES OF ELECTIONS AND DOES NOT EMPLOY ANY REGISTERED LOBBYISTS. PATH PROVIDES BEHIND-THE-SCENES SUPPORT TO ADVOCACY PARTNERS IN THE PLACES WHERE WE WORK TO HELP STRENGTHEN THEIR CAPACITY TO ENGAGE WITH LOCAL DECISION-MAKERS TO IMPROVE HEALTH IN THEIR COMMUNITIES. WE FACILITATE PEER-TO-PEER LEARNINGS AMONG THESE PARTNERS TO EXCHANGE BEST PRACTICES AND LESSONS LEARNED ABOUT THE PRACTICE OF ADVOCACY, AND WE HELP ELEVATE LOCAL VOICES IN GLOBAL CONVERSATIONS AROUND HEALTH. IN 2021, PATH LED EFFORTS TO ENSURE SUPPORT AMONG OUR PARTNER POLICYMAKERS TO MAINTAIN AND STRENGTHEN PIVOTAL WORK IN GLOBAL HEALTH RESEARCH AND DEVELOPMENT, MATERNAL AND CHILD HEALTH, IMMUNIZATION, PHC, AND PANDEMIC PREPAREDNESS AND RESPONSE. SUCCESSES INCLUDED PROTECTING KEY U.S. GOVERNMENT FUNDING FOR PATH'S PRIORITY HEALTH AREAS AND HELPING DECISION-MAKERS SHAPE THE GLOBAL RESPONSE TO COVID-19.ASIA, MIDDLE EAST, AND EUROPE REGIONPATH'S LEADERSHIP IN THE ASIA, MIDDLE EAST, AND EUROPE (AMEE) REGION LEVERAGES OUR DEEP EXPERTISE ACROSS MULTIPLE HEALTH DISCIPLINES TO CHAMPION EQUITY IN ACCESS TO CARE, INTRODUCE NEW TECHNOLOGIES AND APPROACHES, AND PARTNER ACROSS SECTORS TO PROVIDE HUMAN-CENTERED CARE AND SUPPORT. PATH COORDINATES OUR WORK IN THIS REGION FROM OFFICES IN EIGHT COUNTRIES, INCLUDING OFFICES IN CHINA, INDIA, UKRAINE, AND VIETNAM THAT SERVE AS REGIONAL HUBS FOR TECHNICAL AND SCIENTIFIC INNOVATION. HIGHLIGHTS INCLUDE:IN 2021, PATH CONTINUED TO COLLABORATE CLOSELY WITH STAKEHOLDERS TO DELIVER HIGH-QUALITY HEALTH SERVICES WHILE FORGING NEW PARTNERSHIPS IN COUNTRIES SUCH AS BANGLADESH, INDONESIA, LAOS, AND NEPAL AND EXPLORING COLLABORATIONS IN NEW GEOGRAPHIES IN THE MIDDLE EAST.PATH PREPARED AND RESPONDED TO EMERGING HEALTH THREATS IN THE REGION BY PROVIDING TECHNICAL SUPPORT, ENHANCING LABORATORY CAPACITY, STRENGTHENING RESPIRATORY CARE RESPONSE, IMPROVING THE COVID-19 SURVEILLANCE SYSTEM, AND LEVERAGING OUR NETWORK OF PARTNERS TO SUPPORT PANDEMIC RESPONSE. IN ADDITION TO THE COVID-19 EMERGENCY, WE COMMITTED TO ELIMINATE LONG-NEGLECTED DISEASES SUCH AS LEISHMANIASIS AND ENSURE THAT THOSE INFECTED RECEIVE CARE.THANKS TO OUR CONTINUOUS WORK IN DEVELOPING INNOVATIVE DIGITAL HEALTH TOOLS, PATH WAS ABLE TO MAINTAIN ESSENTIAL HEALTH SERVICES FOR KEY POPULATIONS IN MYANMAR, DIGITIZE THE LACTATION MANAGEMENT SYSTEM IN INDIA, AND SUPPORT MEDICATION ADHERENCE FOR TB PATIENTS IN UKRAINE. THROUGHOUT THE YEAR, AMEE PROGRAMS FOCUSED ON INCREASING HEALTH SYSTEM CAPACITY AND RESILIENCE WITH COMMUNITY-BASED APPROACHES THAT BRING AWARENESS, AVAILABILITY, AND ACCESSIBILITY OF HEALTH SERVICES TO HARD-TO-REACH COMMUNITIES. IN VIETNAM, FOR EXAMPLE, WE IMPLEMENTED A HIGHLY SUCCESSFUL PROGRAM FOR HIV SELF-TESTING. PATH IN THE AMEE REGION ALSO CONTINUED OUR CLOSE COLLABORATION WITH WHO, UNICEF, GAVI, AND THE GLOBAL FUND ON LARGE-SCALE EFFORTS TO CONTROL AND ELIMINATE DEBILITATING DISEASES SUCH AS MALARIA AND MENINGITIS; TO IMPROVE ACCESS TO LIFESAVING VACCINES FOR CERVICAL CANCER, DIARRHEAL DISEASE, AND PNEUMOCOCCAL DISEASE IN LOW-INCOME COUNTRIES; AND TO STRENGTHEN VACCINE MANUFACTURING CAPACITY AND THE COLD CHAIN AS PART OF OUR ONGOING EFFORTS TO BRING HEALTH AND WELL-BEING TO ALL. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $41,899,328 | TotalOtherProgSrvcExpenseAmt |
| Total Other Prog Srvc Grant | $5,057,232 | TotalOtherProgSrvcGrantAmt |
| Total Program Service Expenses | $301,134,100 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (1) | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | Yes (1) | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | 0 | ReportOtherAssetsInd |
| Report Other Liabilities | 0 | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | 0 | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | 0 | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | Yes (1) | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | Yes (1) | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (1) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | 0 | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | 0 | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | 0 | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | Yes (1) | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | 0 | DisregardedEntityInd |
| Related Entity | Yes (1) | RelatedEntityInd |
| Related Organization Ctrl Ent | Yes (1) | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | Yes (1) | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| Info In Schedule O Part V | Yes (X) | InfoInScheduleOPartVInd |
| IRP Document | 219 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (1) | BackupWthldComplianceInd |
| Employee | 667 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | 0 | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | Yes (1) | ForeignFinancialAccountInd |
| Foreign Country | BE | ForeignCountryCd |
| Foreign Country | CH | ForeignCountryCd |
| Foreign Country | ET | ForeignCountryCd |
| Foreign Country | GH | ForeignCountryCd |
| Foreign Country | IN | ForeignCountryCd |
| Foreign Country | KE | ForeignCountryCd |
| Foreign Country | MZ | ForeignCountryCd |
| Foreign Country | PE | ForeignCountryCd |
| Foreign Country | SG | ForeignCountryCd |
| Foreign Country | SZ | ForeignCountryCd |
| Foreign Country | TZ | ForeignCountryCd |
| Foreign Country | UG | ForeignCountryCd |
| Foreign Country | UK | ForeignCountryCd |
| Foreign Country | VM | ForeignCountryCd |
| Foreign Country | ZA | ForeignCountryCd |
| Foreign Country | CG | ForeignCountryCd |
| Foreign Country | MI | ForeignCountryCd |
| Foreign Country | BM | ForeignCountryCd |
| Foreign Country | SF | ForeignCountryCd |
| Foreign Country | UP | ForeignCountryCd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | 0 | QuidProQuoContributionsInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | 0 | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | 0 | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 16 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 16 | IndependentVotingMemberCnt |
| Family Or Business Rln | 0 | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | 0 | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | 0 | MembersOrStockholdersInd |
| Election Of Board Members | 0 | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (1) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | AL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | FL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MD | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NJ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NM | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | RI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | SC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | TN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | UT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | VA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WV | StatesWhereCopyOfReturnIsFldCd |
| Own Website | Yes (X) | OwnWebsiteInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | KELLY PRIESTLEY CONTROLLER & PRINCIPAL FINANCIAL OFFICER | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 2062853500 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 2201 WESTLAKE AVE SUITE 200 | AddressLine1Txt |
| City | SEATTLE | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98121 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (33 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd | Former Ofcr Director TrusteeFormerOfcrDirectorTrusteeInd |
|---|---|---|---|---|---|---|---|---|---|---|
| BETH GALETTI MBA | ||||||||||
| CHAIR | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | |||
| DAVID KING JD | ||||||||||
| VICE CHAIR | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | |||
| SANFORD MELZER | ||||||||||
| SECRETARY | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | |||
| BRUCE MCNAMER JD MBA | ||||||||||
| TREASURER | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | |||
| YEHONG ZHANG PHD MBA | ||||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | ||||
| JO ADDY MBA MPA | ||||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | ||||
| IREENA VITTAL | ||||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | ||||
| DEANNA OPPENHEIMER | ||||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | ||||
| JOHN-ARNE ROTTINGEN MD PHD | ||||||||||
| MSC, MPA--DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | ||||
| JOEL HOLSINGER | ||||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | ||||
| HELENA WAYTH MSC | ||||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | ||||
| ABAYOMI SULE MBBS MBA | ||||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | ||||
| LISA ANDERSON | ||||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | ||||
| RACHEL SIBANDE MSC | ||||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | ||||
| FREDERICK WERE | ||||||||||
| DIRECTOR (BEGAN 3/2021) | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | ||||
| LUTZ HEGEMANN MD PHD | ||||||||||
| DIRECTOR (BEGAN 6/2021) | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | ||||
| NIKOLAJ JESTED GILBERT MSC | ||||||||||
| PRESIDENT AND CEO | 39.00 | 1.00 | Yes (X) | $591,896 | $0 | $43,730 | ||||
| JERRY KUO MBA | ||||||||||
| CHIEF OF STRGC. FIN. (UNTIL 1/4/21) | 39.00 | 1.00 | Yes (X) | $134,055 | $0 | $4,302 | ||||
| PHILIPPE GUINOT MBA | ||||||||||
| CHIEF OF BUSINESS, FIN. & OPERATIONS | 1.00 | 39.00 | Yes (X) | $0 | $316,221 | $25,825 | ||||
| DAVID C KASLOW MD | ||||||||||
| CHIEF EXECUTIVE-ESSENTIAL MEDICINES | 39.00 | 1.00 | $408,184 | $0 | $67,963 | Yes (X) | ||||
| JEFFREY D BERNSON MPH MPA | ||||||||||
| CHIEF EXECUTIVE-PROGRAM & INNOVATION | 40.00 | 0.00 | $322,840 | $0 | $58,884 | Yes (X) | ||||
| DAVID W FLEMING--SENIOR VP MD | ||||||||||
| OF PUBLIC HEALTH(UNTIL 2/11/21) | 40.00 | 0.00 | $241,202 | $0 | $10,041 | Yes (X) | ||||
| CARLA ANNE COSTA SANDINE | ||||||||||
| CHIEF OF EXTERNAL AFFAIRS | 40.00 | 0.00 | $268,166 | $0 | $46,608 | Yes (X) | ||||
| MOLLI M BARNES | ||||||||||
| CHIEF PEOPLE OFFICER | 40.00 | 0.00 | $261,290 | $0 | $49,413 | Yes (X) | ||||
| ERICA JANE SESSLE MPHIL MPH | ||||||||||
| CHIEF OF STAFF (UNTIL 10/1/21) | 40.00 | 0.00 | $355,383 | $0 | $40,626 | Yes (X) | ||||
| NANTHALILE C MUGALA MD MMED | ||||||||||
| CHIEF EXECUTIVE-AFRICA REGION | 40.00 | 0.00 | $288,679 | $0 | $0 | Yes (X) | ||||
| SABRINA L POWERS JD | ||||||||||
| GENERAL COUNSEL | 40.00 | 0.00 | $265,189 | $0 | $44,732 | Yes (X) | ||||
| TRAD M HATTON MA MHS | ||||||||||
| COUNTRY DIRECTOR | 40.00 | 0.00 | $345,991 | $0 | $52,997 | Yes (X) | ||||
| KIMBERLY GREEN PHD | ||||||||||
| DIRECTOR, PRIMARY HEALTH CARE | 40.00 | 0.00 | $322,267 | $0 | $60,231 | Yes (X) | ||||
| ASHLEY J BIRKETT PHD | ||||||||||
| GLOBAL HEAD, MALARIA VACCINES | 40.00 | 0.00 | $330,205 | $0 | $59,071 | Yes (X) | ||||
| BRUCE LAMONT INNIS MD FIDSA | ||||||||||
| GLOBAL HEAD, RESPIRATORY INFECTIONS & MATERNAL IMM | 40.00 | 0.00 | $342,216 | $0 | $30,989 | Yes (X) | ||||
| JOHN O KONZ PHD | ||||||||||
| GLOBAL HEAD, INT. PTFL. & FIN. MGMT. | 40.00 | 0.00 | $330,414 | $0 | $64,894 | Yes (X) | ||||
| ELAINE L GIBBONS CFA | ||||||||||
| FRMR VP-GLOBAL ENGMT. (LEFT 2020) | 40.00 | 0.00 | $184,790 | $0 | $2,056 | Yes (X) | ||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $4,992,767 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $316,221 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $662,362 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 354 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | Yes (1) | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/ForeignAddress/AddressLine1Txt | CityContractorAddress/ForeignAddress/CityNm | CountryContractorAddress/ForeignAddress/CountryCd | Foreign PostalContractorAddress/ForeignAddress/ForeignPostalCd | ServicesServicesDesc | CompensationCompensationAmt | Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd |
|---|---|---|---|---|---|---|---|---|---|
| RANDSTAD INDIA PVT LTD | |||||||||
| SUITE NO 001 002 COPIA | NEW DELHI | IN | 110025 | STAFFING SERVICES | $1,796,178 | ||||
| SAFEGUARD WORLD INT'L | |||||||||
| MOSS LANE EDWIN FODEN BUS CENTRE | SANDBACH | UK | CW113AE | GENERAL CONTRACTOR | $1,322,299 | ||||
| UNIT4 BUSINESS SOFTWARE INC | |||||||||
| SYSTEMS CONTRACTOR | $729,988 | 3 BURLINGTON WOODS | BURLINGTON | MA | 01803 | ||||
| PIVOTAL CONSULTING LLC | |||||||||
| CONSULTING | $600,556 | 1631 15TH AVE W 118 | SEATTLE | WA | 98119 | ||||
| GLOBALIZATION PARTNERS INC | |||||||||
| STAFFING SERVICES | $464,096 | 175 FEDERAL ST 17TH FL | BOSTON | MA | 02110 | ||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 41 | CntrctRcvdGreaterThan100KCnt |
| Related Organizations | $2,279,943 | RelatedOrganizationsAmt |
| Government Grants | $113,800,820 | GovernmentGrantsAmt |
| All Other Contributions | $216,988,196 | AllOtherContributionsAmt |
| Noncash Contributions | $3,097,897 | NoncashContributionsAmt |
| Total Contributions | $333,068,959 | TotalContributionsAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $8,920,472 | TotalRevenueColumnAmt |
| Exclusion | $8,920,472 | ExclusionAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $56,047,000 | SecuritiesAmt |
| Other | $22,137 | OtherAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $55,614,599 | SecuritiesAmt |
| Other | $169,653 | OtherAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $432,401 | SecuritiesAmt |
| Other | -$147,516 | OtherAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $284,885 | TotalRevenueColumnAmt |
| Exclusion | $284,885 | ExclusionAmt |
Other Revenue Misc OtherRevenueMiscGrp (2 entries)
| DescDesc | BusinessBusinessCd | Total Revenue ColumnTotalRevenueColumnAmt | ExclusionExclusionAmt |
|---|---|---|---|
| OTHER | 900099 | $804,482 | $804,482 |
| REIMBURSEMENTS | 900099 | $38,788 | $38,788 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $843,270 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $343,117,586 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $0 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $10,048,627 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $24,971,209 | TotalAmt |
| Program Services | $24,971,209 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $50,990,746 | TotalAmt |
| Program Services | $50,990,746 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,503,184 | TotalAmt |
| Program Services | $304,810 | ProgramServicesAmt |
| Management And General | $3,198,374 | ManagementAndGeneralAmt |
Comp Disqual Persons CompDisqualPersonsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $186,846 | TotalAmt |
| Management And General | $186,846 | ManagementAndGeneralAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $98,900,832 | TotalAmt |
| Program Services | $84,542,681 | ProgramServicesAmt |
| Management And General | $12,401,955 | ManagementAndGeneralAmt |
| Fundraising | $1,956,196 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $10,846,071 | TotalAmt |
| Program Services | $9,740,836 | ProgramServicesAmt |
| Management And General | $866,213 | ManagementAndGeneralAmt |
| Fundraising | $239,022 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $15,530,594 | TotalAmt |
| Program Services | $14,465,840 | ProgramServicesAmt |
| Management And General | $968,297 | ManagementAndGeneralAmt |
| Fundraising | $96,457 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $6,439,800 | TotalAmt |
| Program Services | $5,787,905 | ProgramServicesAmt |
| Management And General | $592,796 | ManagementAndGeneralAmt |
| Fundraising | $59,099 | FundraisingAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,361,906 | TotalAmt |
| Program Services | $689,129 | ProgramServicesAmt |
| Management And General | $669,780 | ManagementAndGeneralAmt |
| Fundraising | $2,997 | FundraisingAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $941,141 | TotalAmt |
| Program Services | $234,102 | ProgramServicesAmt |
| Management And General | $707,039 | ManagementAndGeneralAmt |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $335,619 | TotalAmt |
| Management And General | $335,619 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $21,356,638 | TotalAmt |
| Program Services | $16,798,933 | ProgramServicesAmt |
| Management And General | $4,206,724 | ManagementAndGeneralAmt |
| Fundraising | $350,981 | FundraisingAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $259,645 | TotalAmt |
| Program Services | $204,097 | ProgramServicesAmt |
| Management And General | $5,771 | ManagementAndGeneralAmt |
| Fundraising | $49,777 | FundraisingAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $8,500,810 | TotalAmt |
| Program Services | $8,062,238 | ProgramServicesAmt |
| Management And General | $346,509 | ManagementAndGeneralAmt |
| Fundraising | $92,063 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $7,759,274 | TotalAmt |
| Program Services | $6,314,353 | ProgramServicesAmt |
| Management And General | $1,383,166 | ManagementAndGeneralAmt |
| Fundraising | $61,755 | FundraisingAmt |
Royalties RoyaltiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $40,100 | TotalAmt |
| Program Services | $40,100 | ProgramServicesAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $13,663,995 | TotalAmt |
| Program Services | $254,156 | ProgramServicesAmt |
| Management And General | $13,408,822 | ManagementAndGeneralAmt |
| Fundraising | $1,017 | FundraisingAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $8,854,734 | TotalAmt |
| Program Services | $8,756,823 | ProgramServicesAmt |
| Management And General | $97,562 | ManagementAndGeneralAmt |
| Fundraising | $349 | FundraisingAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $8,927,984 | TotalAmt |
| Program Services | $8,672,961 | ProgramServicesAmt |
| Management And General | $254,256 | ManagementAndGeneralAmt |
| Fundraising | $767 | FundraisingAmt |
Interest InterestGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $14 | TotalAmt |
| Program Services | $14 | ProgramServicesAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,442,094 | TotalAmt |
| Program Services | $9,302 | ProgramServicesAmt |
| Management And General | $2,432,792 | ManagementAndGeneralAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $760,860 | TotalAmt |
| Program Services | $460,013 | ProgramServicesAmt |
| Management And General | $300,847 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt | FundraisingFundraisingAmt |
|---|---|---|---|---|
| SUBCONTRACTORS | $32,708,095 | $32,708,095 | ||
| EQUIP RENT & MAINT | $11,123,049 | $10,973,340 | $149,709 | |
| DIRECT AID TO BENEF. | $986,176 | $986,176 | ||
| FACILITIES ALLOC | $0 | $13,860,521 | -$14,219,377 | $358,856 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,953,213 | TotalAmt |
| Program Services | $1,305,720 | ProgramServicesAmt |
| Management And General | $249,627 | ManagementAndGeneralAmt |
| Fundraising | $2,397,866 | FundraisingAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $335,344,629 | TotalAmt |
| Program Services | $301,134,100 | ProgramServicesAmt |
| Management And General | $28,543,327 | ManagementAndGeneralAmt |
| Fundraising | $5,667,202 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $7,194,550 | BOYAmt |
| EOY | $12,911,863 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $9,719,000 | BOYAmt |
| EOY | $10,006,728 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $39,742,632 | BOYAmt |
| EOY | $38,296,068 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $258,036 | BOYAmt |
| EOY | $555,337 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $7,008,112 | BOYAmt |
| EOY | $7,454,031 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $37,891,859 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $30,772,154 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $8,413,303 | BOYAmt |
| EOY | $7,119,705 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $211,220,570 | BOYAmt |
| EOY | $230,729,600 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $283,556,203 | BOYAmt |
| EOY | $307,073,332 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $234,982,056 | BOYAmt |
| EOY | $253,115,813 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $234,982,056 | BOYAmt |
| EOY | $253,115,813 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows FASB117 | Yes (X) | OrganizationFollowsFASB117Ind |
No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $21,554,594 | BOYAmt |
| EOY | $20,653,709 | EOYAmt |
Donor Restriction Net Assets DonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $27,019,553 | BOYAmt |
| EOY | $33,303,810 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $48,574,147 | BOYAmt |
| EOY | $53,957,519 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $283,556,203 | BOYAmt |
| EOY | $307,073,332 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | $7,772,957 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | -$2,389,585 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | $0 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Consolidated Basis Fincl Stmt | Yes (X) | ConsolidatedBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | Yes (1) | FederalGrantAuditRequiredInd |
| Federal Grant Audit Performed | Yes (1) | FederalGrantAuditPerformedInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $347,844,394 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $305,316,107 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $286,808,545 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $287,454,383 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $333,068,959 | CurrentTaxYearAmt |
| Total | $1,560,492,388 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $347,844,394 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $305,316,107 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $286,808,545 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $287,454,383 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $333,068,959 | CurrentTaxYearAmt |
| Total | $1,560,492,388 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $717,318,521 | SubstantialContributorsTotAmt |
| Public Support Total170 | $843,173,867 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $2,050,888 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $2,963,587 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $6,310,221 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $12,207,084 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $8,920,472 | CurrentTaxYearAmt |
| Total | $32,452,252 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $5,225,302 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $980,560 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $836,870 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $1,030,112 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $843,270 | CurrentTaxYearAmt |
| Total | $8,916,114 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $1,601,860,754 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $45,487 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.52640 | PublicSupportCY170Pct |
| Public Support PY170 | 0.53680 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
Total Grassroots Lobbying TotalGrassrootsLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $29,340 | FilingOrganizationsTotalAmt |
Total Direct Lobbying TotalDirectLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $177,826 | FilingOrganizationsTotalAmt |
Total Lobbying Expend TotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $207,166 | FilingOrganizationsTotalAmt |
Other Exempt Purpose Expend OtherExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $335,137,463 | FilingOrganizationsTotalAmt |
Total Exempt Purpose Expend TotalExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $335,344,629 | FilingOrganizationsTotalAmt |
Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $1,000,000 | FilingOrganizationsTotalAmt |
Grassroots Nontaxable GrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $250,000 | FilingOrganizationsTotalAmt |
Tot Lbbyng Grassroot Mns Non Tx TotLbbyngGrassrootMnsNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Tot Lbby Expend Mns Lbbyng Non Tx TotLbbyExpendMnsLbbyngNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $1,000,000 | CurrentYearMinus3Amt |
| Current Year Minus2 | $1,000,000 | CurrentYearMinus2Amt |
| Current Year Minus1 | $1,000,000 | CurrentYearMinus1Amt |
| Current Year | $1,000,000 | CurrentYearAmt |
| Total | $4,000,000 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Lobbying Ceiling | $6,000,000 | LobbyingCeilingAmt |
Avg Total Lobbying Expend AvgTotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $224,944 | CurrentYearMinus3Amt |
| Current Year Minus2 | $163,912 | CurrentYearMinus2Amt |
| Current Year Minus1 | $135,193 | CurrentYearMinus1Amt |
| Current Year | $207,166 | CurrentYearAmt |
| Total | $731,215 | TotalAmt |
Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $250,000 | CurrentYearMinus3Amt |
| Current Year Minus2 | $250,000 | CurrentYearMinus2Amt |
| Current Year Minus1 | $250,000 | CurrentYearMinus1Amt |
| Current Year | $250,000 | CurrentYearAmt |
| Total | $1,000,000 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grassroots Ceiling | $1,500,000 | GrassrootsCeilingAmt |
Avg Grassroots Lobbying Expend AvgGrassrootsLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $7,856 | CurrentYearMinus3Amt |
| Current Year Minus1 | $405 | CurrentYearMinus1Amt |
| Current Year | $29,340 | CurrentYearAmt |
| Total | $37,601 | TotalAmt |
Schedule D IRS990ScheduleD
CY Endwmt Fund CYEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $10,930,723 | BeginningYearBalanceAmt |
| Contributions | $2,500 | ContributionsAmt |
| Investment Earnings Or Losses | $1,323,367 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $514,376 | OtherExpendituresAmt |
| End Year Balance | $11,742,214 | EndYearBalanceAmt |
CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $10,287,113 | BeginningYearBalanceAmt |
| Contributions | $2,745 | ContributionsAmt |
| Investment Earnings Or Losses | $1,095,576 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $454,711 | OtherExpendituresAmt |
| End Year Balance | $10,930,723 | EndYearBalanceAmt |
CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $9,095,917 | BeginningYearBalanceAmt |
| Contributions | $2,100 | ContributionsAmt |
| Investment Earnings Or Losses | $1,691,617 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $502,521 | OtherExpendituresAmt |
| End Year Balance | $10,287,113 | EndYearBalanceAmt |
CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $10,056,545 | BeginningYearBalanceAmt |
| Contributions | $1,240 | ContributionsAmt |
| Investment Earnings Or Losses | -$494,491 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $467,377 | OtherExpendituresAmt |
| End Year Balance | $9,095,917 | EndYearBalanceAmt |
CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $9,339,249 | BeginningYearBalanceAmt |
| Contributions | $3,410 | ContributionsAmt |
| Investment Earnings Or Losses | $1,159,282 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $445,396 | OtherExpendituresAmt |
| End Year Balance | $10,056,545 | EndYearBalanceAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Board Designated Balance EOY | 0.36000 | BoardDesignatedBalanceEOYPct |
| Prmnnt Endowment Balance EOY | 0.29000 | PrmnntEndowmentBalanceEOYPct |
| Term Endowment Balance EOY | 0.35000 | TermEndowmentBalanceEOYPct |
| Endowments Held Unrelated Org | 0 | EndowmentsHeldUnrelatedOrgInd |
| Endowments Held Related Org | 0 | EndowmentsHeldRelatedOrgInd |
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $22,543,573 | OtherCostOrOtherBasisAmt |
| Depreciation | $17,259,728 | DepreciationAmt |
| Book Value | $5,283,845 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $9,534,680 | OtherCostOrOtherBasisAmt |
| Depreciation | $8,349,319 | DepreciationAmt |
| Book Value | $1,185,361 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $5,813,606 | OtherCostOrOtherBasisAmt |
| Depreciation | $5,163,107 | DepreciationAmt |
| Book Value | $650,499 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $7,119,705 | TotalBookValueLandBuildingsAmt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART V, LINE 4: | FormAndLineReferenceDesc |
| Explanation | PATH UTILIZES THE INVESTED INTEREST EARNINGS FROM THE ENDOWMENT AS AN IMPORTANT FUNDING SOURCE TO FUND NEW OPPORTUNITIES TO EXPAND ITS REACH AND IMPACT AS AN ORGANIZATION IN THE FIELD OF GLOBAL HEALTH, IN ACCORDANCE WITH PATH'S ENDOWMENT SPENDING POLICY. | ExplanationTxt |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (63 entries)
| RegionRegionTxt | OfficesOfficesCnt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|---|---|
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | PROGRAM SERVICES | AFRICA | $217,383 |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | PROGRAM SERVICES | AMEE | $165,240 |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | BID & PROPOSAL | BID & PROPOSAL | $33,612 |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $1,261,725 |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | FUNDRAISING | FUNDRAISING | $109,157 |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | MANAGEMENT & GENERAL | MANAGEMENT & GENERAL | $1,777,579 |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | PROGRAM SERVICES | OTHER | $62,676 |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | PROGRAM SERVICES | PROGRAM INNOVATION | $920,872 |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | GRANTMAKING | $929,969 | |
| EAST ASIA AND THE PACIFIC | 5 | 118 | PROGRAM SERVICES | AMEE | $6,547,799 |
| EAST ASIA AND THE PACIFIC | 0 | 0 | BID & PROPOSAL | BID & PROPOSAL | $82,678 |
| EAST ASIA AND THE PACIFIC | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $7,846,097 |
| EAST ASIA AND THE PACIFIC | 0 | 0 | FUNDRAISING | FUNDRAISING | $2,700 |
| EAST ASIA AND THE PACIFIC | 0 | 0 | MANAGEMENT & GENERAL | MANAGEMENT & GENERAL | $1,576,557 |
| EAST ASIA AND THE PACIFIC | 0 | 0 | PROGRAM SERVICES | OTHER | $54,699 |
| EAST ASIA AND THE PACIFIC | 0 | 0 | PROGRAM SERVICES | PROGRAM INNOVATION | $2,386,560 |
| EAST ASIA AND THE PACIFIC | 0 | 0 | GRANTMAKING | $9,766,636 | |
| EUROPE | 1 | 5 | PROGRAM SERVICES | AFRICA | $132,045 |
| EUROPE | 0 | 0 | PROGRAM SERVICES | AMEE | $682,847 |
| EUROPE | 0 | 0 | BID & PROPOSAL | BID & PROPOSAL | $10,044 |
| EUROPE | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $17,261,790 |
| EUROPE | 0 | 0 | MANAGEMENT & GENERAL | MANAGEMENT & GENERAL | $2,419,101 |
| EUROPE | 0 | 0 | PROGRAM SERVICES | OTHER | $51,211 |
| EUROPE | 0 | 0 | PROGRAM SERVICES | PROGRAM INNOVATION | $11,174,147 |
| EUROPE | 0 | 0 | GRANTMAKING | $20,410,132 | |
| MIDDLE EAST AND NORTH AFRICA | 0 | 0 | PROGRAM SERVICES | PROGRAM INNOVATION | $18,176 |
| MIDDLE EAST AND NORTH AFRICA | 0 | 0 | GRANTMAKING | $10,000 | |
| NORTH AMERICA | 0 | 0 | PROGRAM SERVICES | AFRICA | $9,600 |
| NORTH AMERICA | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $616,112 |
| NORTH AMERICA | 0 | 0 | FUNDRAISING | FUNDRAISING | $4,995 |
| NORTH AMERICA | 0 | 0 | MANAGEMENT & GENERAL | MANAGEMENT & GENERAL | $88,345 |
| NORTH AMERICA | 0 | 0 | PROGRAM SERVICES | OTHER | $23,285 |
| NORTH AMERICA | 0 | 0 | PROGRAM SERVICES | PROGRAM INNOVATION | $699,541 |
| NORTH AMERICA | 0 | 0 | GRANTMAKING | $706,919 | |
| RUSSIA AND NEIGHBORING STATES | 1 | 25 | PROGRAM SERVICES | AMEE | $3,464,908 |
| RUSSIA AND NEIGHBORING STATES | 0 | 0 | BID & PROPOSAL | BID & PROPOSAL | $19,196 |
| RUSSIA AND NEIGHBORING STATES | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $399 |
| RUSSIA AND NEIGHBORING STATES | 0 | 0 | MANAGEMENT & GENERAL | MANAGEMENT & GENERAL | $653,450 |
| RUSSIA AND NEIGHBORING STATES | 0 | 0 | PROGRAM SERVICES | PROGRAM INNOVATION | $128,590 |
| RUSSIA AND NEIGHBORING STATES | 0 | 0 | GRANTMAKING | $1,829,202 | |
| SOUTH AMERICA | 1 | 5 | BID & PROPOSAL | BID & PROPOSAL | $610 |
| SOUTH AMERICA | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $593,454 |
| SOUTH AMERICA | 0 | 0 | MANAGEMENT & GENERAL | MANAGEMENT & GENERAL | $33,701 |
| SOUTH AMERICA | 0 | 0 | PROGRAM SERVICES | OTHER | $1,080 |
| SOUTH AMERICA | 0 | 0 | PROGRAM SERVICES | PROGRAM INNOVATION | $847,838 |
| SOUTH AMERICA | 0 | 0 | GRANTMAKING | $1,068,327 | |
| SOUTH ASIA | 5 | 173 | PROGRAM SERVICES | AFRICA | $14,620 |
| SOUTH ASIA | 0 | 0 | PROGRAM SERVICES | AMEE | $14,176,008 |
| SOUTH ASIA | 0 | 0 | BID & PROPOSAL | BID & PROPOSAL | $48,403 |
| SOUTH ASIA | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $3,906,531 |
| SOUTH ASIA | 0 | 0 | MANAGEMENT & GENERAL | MANAGEMENT & GENERAL | $2,581,026 |
| SOUTH ASIA | 0 | 0 | PROGRAM SERVICES | OTHER | $14,339 |
| SOUTH ASIA | 0 | 0 | PROGRAM SERVICES | PROGRAM INNOVATION | $1,444,393 |
| SOUTH ASIA | 0 | 0 | GRANTMAKING | $2,589,327 | |
| SUB-SAHARAN AFRICA | 41 | 723 | PROGRAM SERVICES | AFRICA | $26,446,647 |
| SUB-SAHARAN AFRICA | 0 | 0 | PROGRAM SERVICES | AMEE | $13,792 |
| SUB-SAHARAN AFRICA | 0 | 0 | BID & PROPOSAL | BID & PROPOSAL | $196,707 |
| SUB-SAHARAN AFRICA | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $9,523,251 |
| SUB-SAHARAN AFRICA | 0 | 0 | FUNDRAISING | FUNDRAISING | $815 |
| SUB-SAHARAN AFRICA | 0 | 0 | MANAGEMENT & GENERAL | MANAGEMENT & GENERAL | $10,904,369 |
| SUB-SAHARAN AFRICA | 0 | 0 | PROGRAM SERVICES | OTHER | $2,666,469 |
| SUB-SAHARAN AFRICA | 0 | 0 | PROGRAM SERVICES | PROGRAM INNOVATION | $26,394,347 |
| SUB-SAHARAN AFRICA | 0 | 0 | GRANTMAKING | $13,680,233 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 0 | SubtotalOfficesCnt |
| Subtotal Employees | 0 | SubtotalEmployeesCnt |
| Continuation Total Office | 54 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 1049 | ContinuationTotalEmployeeCnt |
| Total Office | 54 | TotalOfficeCnt |
| Total Employee | 1049 | TotalEmployeeCnt |
| Subtotal Spent | $4,548,244 | SubtotalSpentAmt |
| Continuation Spent | $206,754,017 | ContinuationSpentAmt |
| Total Spent | $211,302,261 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (216 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt | Non Cash AssistanceNonCashAssistanceAmt |
|---|---|---|---|---|
| CENTRAL AMERICA AND THE CARIBBEAN | ESSENTIAL MEDICINE | $227,985 | CHECK/WIRE | $0 |
| CENTRAL AMERICA AND THE CARIBBEAN | ESSENTIAL MEDICINE | $15,000 | CHECK/WIRE | $0 |
| CENTRAL AMERICA AND THE CARIBBEAN | PROGRAM INNOVATION | $10,524 | CHECK/WIRE | $0 |
| CENTRAL AMERICA AND THE CARIBBEAN | ESSENTIAL MEDICINE | $215,408 | CHECK/WIRE | $0 |
| CENTRAL AMERICA AND THE CARIBBEAN | ESSENTIAL MEDICINE | $361,052 | CHECK/WIRE | $0 |
| CENTRAL AMERICA AND THE CARIBBEAN | PROGRAM INNOVATION | $30,000 | CHECK/WIRE | $0 |
| CENTRAL AMERICA AND THE CARIBBEAN | PROGRAM INNOVATION | $70,000 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | AMEE | $71,479 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | PROGRAM INNOVATION | $79,069 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | PROGRAM INNOVATION | $25,000 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | PROGRAM INNOVATION | $24,100 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | AMEE | $31,654 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | ESSENTIAL MEDICINE | $1,059,500 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | AMEE | $71,326 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | PROGRAM INNOVATION | $57,821 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | AMEE | $166,913 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | AMEE | $24,313 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | AMEE | $91,383 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | AMEE | $42,330 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | PROGRAM INNOVATION | $126,213 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | AMEE | $10,524 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | AMEE | $72,828 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | AMEE | $49,919 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | AMEE | $7,010 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | ESSENTIAL MEDICINE | $271,548 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | AMEE | $129,349 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | PROGRAM INNOVATION | $94,424 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | ESSENTIAL MEDICINE | $218,743 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | PROGRAM INNOVATION | $33,437 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | PROGRAM INNOVATION | $13,508 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | ESSENTIAL MEDICINE & PROGRAM INNOVATION | $1,721,642 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | AMEE | $66,193 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | AMEE | $243,955 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | AMEE | $17,769 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | ESSENTIAL MEDICINE | $3,664,864 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | AMEE | $18,921 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | ESSENTIAL MEDICINE | $150,000 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | PROGRAM INNOVATION | $49,988 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | ESSENTIAL MEDICINE | $222,394 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | AMEE | $117,367 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | AMEE | $288,175 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | PROGRAM INNOVATION | $67,463 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | ESSENTIAL MEDICINE | $23,575 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | PROGRAM INNOVATION | $49,441 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | ESSENTIAL MEDICINE | $29,242 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | AMEE | $83,315 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | AMEE | $11,074 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | AMEE | $34,649 | CHECK/WIRE | $0 |
| EAST ASIA AND THE PACIFIC | PROGRAM INNOVATION | $130,168 | CHECK/WIRE | $0 |
| EUROPE | PROGRAM INNOVATION | $464,778 | CHECK/WIRE | $0 |
| EUROPE | PROGRAM INNOVATION | $38,183 | CHECK/WIRE | $0 |
| EUROPE | ESSENTIAL MEDICINE | $224,974 | CHECK/WIRE | $0 |
| EUROPE | AFRICA | $102,374 | CHECK/WIRE | $0 |
| EUROPE | AMEE | $212,829 | CHECK/WIRE | $0 |
| EUROPE | ESSENTIAL MEDICINE | $1,743,618 | CHECK/WIRE | $0 |
| EUROPE | ESSENTIAL MEDICINE & PROGRAM INNOVATION | $92,712 | CHECK/WIRE | $0 |
| EUROPE | PROGRAM INNOVATION | $29,960 | CHECK/WIRE | $0 |
| EUROPE | PROGRAM INNOVATION | $6,000 | CHECK/WIRE | $0 |
| EUROPE | ESSENTIAL MEDICINE | $600,613 | CHECK/WIRE | $0 |
| EUROPE | ESSENTIAL MEDICINE & PROGRAM INNOVATION | $2,712,511 | CHECK/WIRE | $0 |
| EUROPE | PROGRAM INNOVATION | $49,500 | CHECK/WIRE | $0 |
| EUROPE | PROGRAM INNOVATION | $10,296 | CHECK/WIRE | $0 |
| EUROPE | PROGRAM INNOVATION | $1,026,135 | CHECK/WIRE | $0 |
| EUROPE | PROGRAM INNOVATION | $28,400 | CHECK/WIRE | $0 |
| EUROPE | ESSENTIAL MEDICINE | $279,243 | CHECK/WIRE | $0 |
| EUROPE | PROGRAM INNOVATION | $507,807 | CHECK/WIRE | $0 |
| EUROPE | ESSENTIAL MEDICINE | $853,035 | CHECK/WIRE | $0 |
| EUROPE | PROGRAM INNOVATION | $45,185 | CHECK/WIRE | $0 |
| EUROPE | ESSENTIAL MEDICINE | $124,000 | CHECK/WIRE | $0 |
| EUROPE | ESSENTIAL MEDICINE | $50,000 | CHECK/WIRE | $0 |
| EUROPE | PROGRAM INNOVATION | $88,970 | CHECK/WIRE | $0 |
| EUROPE | PROGRAM INNOVATION | $1,279,135 | CHECK/WIRE | $0 |
| EUROPE | AMEE | $164,921 | CHECK/WIRE | $0 |
| EUROPE | ESSENTIAL MEDICINE | $231,168 | CHECK/WIRE | $0 |
| EUROPE | ESSENTIAL MEDICINE | $881,326 | CHECK/WIRE | $0 |
| EUROPE | ESSENTIAL MEDICINE | $225,000 | CHECK/WIRE | $0 |
| EUROPE | PROGRAM INNOVATION | $1,767,625 | CHECK/WIRE | $0 |
| EUROPE | ESSENTIAL MEDICINE & PROGRAM INNOVATION | $607,577 | CHECK/WIRE | $0 |
| EUROPE | PROGRAM INNOVATION | $40,000 | CHECK/WIRE | $0 |
| EUROPE | PROGRAM INNOVATION | $45,000 | CHECK/WIRE | $0 |
| EUROPE | PROGRAM INNOVATION | $12,461 | CHECK/WIRE | $0 |
| EUROPE | PROGRAM INNOVATION | $75,000 | CHECK/WIRE | $0 |
| EUROPE | AFRICA, AMEE, ESSENTIAL MEDICINE, & PROGRAM INNOVATION | $5,789,794 | CHECK/WIRE | $0 |
| MIDDLE EAST & NORTH AFRICA | PROGRAM INNOVATION | $10,000 | CHECK/WIRE | $0 |
| NORTH AMERICA | ESSENTIAL MEDICINE | $124,774 | CHECK/WIRE | $0 |
| NORTH AMERICA | PROGRAM INNOVATION | $100,000 | CHECK/WIRE | $0 |
| NORTH AMERICA | PROGRAM INNOVATION | $422,975 | CHECK/WIRE | $0 |
| NORTH AMERICA | ESSENTIAL MEDICINE | $59,170 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $13,366 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $85,308 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $45,891 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $45,746 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $17,675 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $82,462 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $29,707 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $25,138 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $14,255 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $176,629 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $18,457 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $449,620 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $39,901 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $17,227 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $32,985 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $67,892 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $17,698 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $19,542 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $41,708 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | PROGRAM INNOVATION | $209,012 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $37,400 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $47,434 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $38,192 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $62,796 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $84,569 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $30,998 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $36,033 | CHECK/WIRE | $0 |
| RUSSIA AND NEIGHBORING STATES | AMEE | $41,560 | CHECK/WIRE | $0 |
| SOUTH AMERICA | PROGRAM INNOVATION | $168,199 | CHECK/WIRE | $0 |
| SOUTH AMERICA | PROGRAM INNOVATION | $20,007 | CHECK/WIRE | $0 |
| SOUTH AMERICA | ESSENTIAL MEDICINE | $362,750 | CHECK/WIRE | $0 |
| SOUTH AMERICA | ESSENTIAL MEDICINE | $74,798 | CHECK/WIRE | $0 |
| SOUTH AMERICA | PROGRAM INNOVATION | $15,000 | CHECK/WIRE | $0 |
| SOUTH AMERICA | PROGRAM INNOVATION | $176,616 | CHECK/WIRE | $0 |
| SOUTH AMERICA | ESSENTIAL MEDICINE | $56,253 | CHECK/WIRE | $0 |
| SOUTH AMERICA | ESSENTIAL MEDICINE | $87,883 | CHECK/WIRE | $0 |
| SOUTH AMERICA | PROGRAM INNOVATION | $106,821 | CHECK/WIRE | $0 |
| SOUTH ASIA | AMEE & PROGRAM INNOVATION | $46,814 | CHECK/WIRE | $0 |
| SOUTH ASIA | ESSENTIAL MEDICINE & PROGRAM INNOVATION | $30,872 | CHECK/WIRE | $0 |
| SOUTH ASIA | AMEE | $142,895 | CHECK/WIRE | $0 |
| SOUTH ASIA | AMEE | $11,937 | CHECK/WIRE | $0 |
| SOUTH ASIA | ESSENTIAL MEDICINE | $35,629 | CHECK/WIRE | $0 |
| SOUTH ASIA | ESSENTIAL MEDICINE | $633,973 | CHECK/WIRE | $0 |
| SOUTH ASIA | PROGRAM INNOVATION | $150,000 | CHECK/WIRE | $0 |
| SOUTH ASIA | PROGRAM INNOVATION | $268,084 | CHECK/WIRE | $0 |
| SOUTH ASIA | AMEE | $10,192 | CHECK/WIRE | $0 |
| SOUTH ASIA | AMEE | $69,757 | CHECK/WIRE | $0 |
| SOUTH ASIA | AMEE | $8,375 | CHECK/WIRE | $0 |
| SOUTH ASIA | ESSENTIAL MEDICINE | $55,000 | CHECK/WIRE | $0 |
| SOUTH ASIA | AMEE | $35,613 | CHECK/WIRE | $0 |
| SOUTH ASIA | ESSENTIAL MEDICINE | $684,743 | CHECK/WIRE | $0 |
| SOUTH ASIA | AMEE | $22,878 | CHECK/WIRE | $0 |
| SOUTH ASIA | AMEE | $11,754 | CHECK/WIRE | $0 |
| SOUTH ASIA | AMEE | $7,440 | CHECK/WIRE | $0 |
| SOUTH ASIA | AMEE & PROGRAM INNOVATION | $187,263 | CHECK/WIRE | $0 |
| SOUTH ASIA | ESSENTIAL MEDICINE | $20,970 | CHECK/WIRE | $0 |
| SOUTH ASIA | ESSENTIAL MEDICINE | $33,198 | CHECK/WIRE | $0 |
| SOUTH ASIA | AMEE & PROGRAM INNOVATION | $118,896 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $13,424 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $15,000 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $21,000 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $6,270 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $62,011 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $99,480 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $41,055 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $227,642 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $12,129 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $12,152 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $35,635 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $157,401 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $162,805 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $6,515 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $1,000,000 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $428,863 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $245,842 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $527,263 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $28,851 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $8,509 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $106,638 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $37,800 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $44,460 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $10,846 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | OTHER & PROGRAM INNOVATION | $115,300 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $60,018 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $104,684 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $7,683 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $12,611 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $10,682 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | OTHER | $8,669 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $537,043 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $539,937 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $399,962 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $246,615 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $247,713 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $491,789 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $58,630 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $475,324 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $26,950 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $124,276 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | OTHER & PROGRAM INNOVATION | $38,832 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $167,358 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $456,000 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | OTHER & PROGRAM INNOVATION | $24,589 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $14,876 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $115,516 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $5,385 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $12,299 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $1,242,616 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $7,690 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $87,022 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $688,202 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $7,828 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $275,719 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $439,041 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $7,372 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $15,000 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $110,443 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $65,000 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $200,000 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA, ESSENTIAL MEDICINE, & PROGRAM INNOVATION | $599,874 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $241,692 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $1,167,548 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $701,521 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $73,356 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $14,584 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $75,234 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | AFRICA | $7,831 | CHECK/WIRE | $0 |
| SUB-SAHARAN AFRICA | PROGRAM INNOVATION | $12,000 | CHECK/WIRE | $0 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 166 | Total501c3OrgCnt |
| Total Other Org | 50 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | Yes (1) | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | 0 | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | 0 | PassiveForeignInvestmestCoInd |
| Foreign Partnership | 0 | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 2: | PATH HAS A SUBRECIPIENT POLICY AND PROCEDURES IN PLACE TO GUIDE THE WAY OUR PROJECT TEAMS MONITOR SUBRECIPIENTS. THIS INCLUDES BOTH FINANCIAL AND TECHNICAL MONITORING. PATH USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, AND OTHER MEANS TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD PROJECT STEWARDSHIP. THESE ACTIVITIES ALSO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS, AND THAT THE SUBRECIPIENT ACHIEVES PERFORMANCE GOALS. PATH HAS ESTABLISHED COMPREHENSIVE POLICIES AND PROCEDURES TO PROMOTE BEST BUSINESS PRACTICES AND ENSURE EFFICIENT AND EFFECTIVE INTERNAL CONTROL. THESE ARE COMBINED WITH AN INTERNAL AUDIT FUNCTION THROUGH WHICH PATH CONDUCTS AUDITS ON GRANT-FUNDED PROGRAMS TO ENSURE COMPLIANCE WITH REGULATORY REQUIREMENTS. |
| PART III ACCOUNTING METHOD: |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (77 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Non Cash AssistanceNonCashAssistanceAmt | Purpose Of GrantPurposeOfGrantTxt | Address Line2USAddress/AddressLine2Txt |
|---|---|---|---|---|---|---|---|---|---|
| ABT ASSOCIATES INC | |||||||||
| 6130 EXECUTIVE BLVD | ROCKVILLE | MD | 20852 | 042347643 | OTHER | $9,708 | $0 | PROGRAM INNOVATION | |
| ADARA DEVELOPMENT (USA) | |||||||||
| 300 ADMIRAL WY SUITE 106 | EDMONDS | WA | 98020 | 980634789 | 501(C)(3) | $93,108 | $0 | PROGRAM INNOVATION | |
| AJINOMOTO ALTHEA INC (DBA AJINOMOTO BIO-PHARMA SERVICES) | |||||||||
| 11040 ROSELLE STREET | SAN DIEGO | CA | 92121 | 330788907 | OTHER | $11,430 | $0 | ESSENTIAL MEDICINES | |
| AKROS INC | |||||||||
| PO BOX 457 | LARAMIE | WY | 82073 | OTHER | $75,197 | $0 | PROGRAM INNOVATION | ||
| BAGAMIAN SCIENTIFIC CONSULTING | |||||||||
| 222 NW 3RD AVE | GAINESVILLE | FL | 32601 | 821347380 | 501(C)(3) | $149,150 | $0 | ESSENTIAL MEDICINES | |
| BENEVOLENT HEALTHCARE FOUNDATION DBA PROJECT CURE | |||||||||
| 10377 E GEDDES AVENUE SUITE 200 | CENTENNIAL | CO | 80112 | 841568566 | 501(C)(3) | $25,153 | $0 | AFRICA | |
| CENTERS FOR DISEASE CONTROL AND PREVENTION | |||||||||
| 1600 CLIFTON ROAD | ATLANTA | GA | 30333 | 586051157 | GOV | $71,634 | $0 | ESSENTIAL MEDICINES | |
| CHILDREN'S HOSPITAL BOSTON | |||||||||
| RESEARCH FINANCE PO BOX 414413 | BOSTON | MA | 022414413 | 042774441 | 501(C)(3) | $377,756 | $0 | ESSENTIAL MEDICINES | |
| CINCINNATI CHILDREN'S HOSPITAL | |||||||||
| MEDICAL CENTER 3333 BURNET AVE ML | CINCINNATI | OH | 452293039 | 310833936 | 501(C)(3) | $230,000 | $0 | ESSENTIAL MEDICINES | 6014 |
| CLINTON HEALTH ACCESS INITIATIVE | |||||||||
| 383 DORCHESTER AVE SUITE 400 | BOSTON | MA | 02127 | 271414646 | 501(C)(3) | $1,821,638 | $0 | PROGRAM INNOVATION | |
| COOPERSMITH | |||||||||
| 4206 RIVER RD NW | WASHINGTON | DC | 20016 | 472387850 | OTHER | $188,947 | $0 | PROGRAM INNOVATION | |
| DARTMOUTH-HITCHCOCK CLINIC | |||||||||
| ONE MEDICAL CENTER DR | LEBANON | NH | 03756 | 222715483 | 501(C)(3) | $199,968 | $0 | ESSENTIAL MEDICINES | |
| DIMAGI INC | |||||||||
| 585 MASSACHUSETTS AVE SUITE 4 | CAMBRIDGE | MA | 02139 | 830343298 | 501(C)(3) | $287,935 | $0 | PROGRAM INNOVATION | |
| FOOD AND DRUG ADMINISTRATION | |||||||||
| 5600 FISHERS LNHFA-140 RM 11-40 | ROCKVILLE | MD | 20857 | 530196965 | GOV | $75,000 | $0 | ESSENTIAL MEDICINES | |
| G&L SCIENTIFIC INC | |||||||||
| 25 INDEPENDENCE BLVD SUITE 404 | WARREN | NJ | 07059 | 811114075 | OTHER | $12,360 | $0 | PROGRAM INNOVATION | |
| GLOBAL CONNECT DEVELOPMENT GROUP LLC | |||||||||
| 480 BEACH ST | BOSTON | MA | 02131 | 823433604 | OTHER | $398,175 | $0 | PROGRAM INNOVATION | |
| GLOBAL HEALTH STRATEGIES LLC | |||||||||
| 27 WEST 24TH STREET SUITE 900 | NEW YORK | NY | 10010 | 272494697 | 501(C)(3) | $264,021 | $0 | PROGRAM INNOVATION | |
| GUARALDI SYSTEMS LLC | |||||||||
| 97 ALGER BROOK RD | SOUTH STAFFORD | VT | 05070 | 851148274 | OTHER | $276,640 | $0 | PROGRAM INNOVATION | |
| HARVARD SCHOOL OF PUBLIC HEALTH | |||||||||
| 677 HUNTINGTON AVENUE | BOSTON | MA | 02215 | 042103580 | 501(C)(3) | $1,415,739 | $0 | ESSENTIAL MEDICINES | |
| HARVARD UNIVERSITY | |||||||||
| 1033 MASSACHUSETTS AVE 2ND FLOOR | CAMBRIDGE | MA | 02115 | 042103580 | 501(C)(3) | $157,819 | $0 | ESSENTIAL MEDICINES & PROGRAM INNOVATION | |
| HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE INC | |||||||||
| 6720-A ROCKLEDGE DRIVE STE 100 | BETHESDA | MD | 20817 | 521317896 | 501(C)(3) | $10,663 | $0 | ESSENTIAL MEDICINES | |
| HISP US LLC | |||||||||
| 31 ANCONA AVE | OCEAN PARK | ME | 04063 | 850894858 | OTHER | $310,352 | $0 | PROGRAM INNOVATION | |
| HJF MEDICAL RESEARCH INTERNATIONAL INC | |||||||||
| 6720A ROCKLEDGE DRIVE SUITE 100 | BETHESDA | MD | 20817 | 522322791 | 501(C)(3) | $63,260 | $0 | ESSENTIAL MEDICINES | |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | |||||||||
| 1 GUSTAVE L LEVY PLACE | NEW YORK | NY | 10029 | 136171197 | 501(C)(3) | $535,000 | $0 | ESSENTIAL MEDICINES | |
| ICF MACRO INC | |||||||||
| 9300 LEE HIGHWAY | FAIRFAX | VA | 22031 | 223661438 | OTHER | $2,049,999 | $0 | PROGRAM INNOVATION | |
| INDIANA UNIVERSITY | |||||||||
| 107 S INDIAN AVE | BLOOMINGTON | IN | 47405 | 356001673 | GOV | $148,623 | $0 | PROGRAM INNOVATION | |
| INTERNATIONAL FOOD POLICY RESEARCH INSTITUTE (IFPRI) | |||||||||
| 1201 EYE STREET NW | WASHINGTON | DC | 20005 | 521041632 | 501(C)(3) | $16,666 | $0 | PROGRAM INNOVATION | |
| INTRAHEALTH INTERNATIONAL INC | |||||||||
| 6340 QUADRANGLE DRIVE SUITE 200 | CHAPEL HILL | NC | 27517 | 550825466 | 501(C)(3) | $824,333 | $0 | AFRICA & PROGRAM INNOVATION | |
| IPAS | |||||||||
| 300 MARKET ST 200 | CHAPEL HILL | NC | 27516 | 561071085 | 501(C)(3) | $63,941 | $0 | PROGRAM INNOVATION | |
| JHPIEGO | |||||||||
| 1615 THAMES STREET SUITE 200 | BALTIMORE | MD | 212313447 | 237424444 | 501(C)(3) | $437,778 | $0 | AFRICA & AMEE | |
| JOHNS HOPKINS UNIVERSITY | |||||||||
| BLOOMBERG SCHL OF PUB HLTH 615 N | BALTIMORE | MD | 21205 | 520595110 | 501(C)(3) | $10,566 | $0 | ESSENTIAL MEDICINES | WOLFE STREET |
| JSI RESEARCH AND TRAINING INSTITUTE INC | |||||||||
| 1616 NORTH FORT MYER DR 16TH FLOOR | ARLINGTON | VA | 222093100 | 042679824 | 501(C)(3) | $1,138,899 | $0 | PROGRAM INNOVATION | |
| KINDEVA DRUG DELIVERY LP | |||||||||
| 11200 HUDSON RD | WOODBURY | MN | 55129 | OTHER | $146,960 | $0 | PROGRAM INNOVATION | ||
| LEIDOS BIOMEDICAL RESEARCH INC | |||||||||
| 1050 BOYLES ST | FREDERICK | MD | 21702 | 330653185 | OTHER | $148,511 | $0 | ESSENTIAL MEDICINES | |
| LINKSBRIDGE SPC | |||||||||
| 101 TAYLOR AVE N 105 | SEATTLE | WA | 98109 | 263067893 | OTHER | $27,849 | $0 | ESSENTIAL MEDICINES | |
| MAGEE-WOMENS RESEARCH INSTITUTE AND FOUNDATION (MWRI) | |||||||||
| 3339 WARD ST | PITTSBURGH | PA | 15213 | 251462312 | 501(C)(3) | $35,761 | $0 | PROGRAM INNOVATION | |
| MANAGEMENT SCIENCES FOR HEALTH INC | |||||||||
| 200 RIVERS EDGE DRIVE SUITE 320 | MEDFORD | MA | 02155 | 042482188 | 501(C)(3) | $111,280 | $0 | PROGRAM INNOVATION | |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| DEPT OF EMERGENCY MEDICINE ZERO | BOSTON | MA | 02114 | 041564655 | 501(C)(3) | $22,298 | $0 | ESSENTIAL MEDICINES | EMERSON PL 104 |
| MEDIC MOBILE INC | |||||||||
| 3254 19TH STREET FLOOR 2 | SAN FRANCISCO | CA | 94110 | 275104203 | 501(C)(3) | $100,439 | $0 | PROGRAM INNOVATION | |
| MICHIGAN STATE UNIVERSITY | |||||||||
| 3900 COLLINS RD SUITE 1044 | LANSING | MI | 48910 | 386005984 | 501(C)(3) | $148,595 | $0 | PROGRAM INNOVATION | |
| NATIONAL FOUNDATION FOR THE CDC | |||||||||
| 55 PARK PLACE SUITE 400 | ATLANTA | GA | 30303 | 582106707 | 501(C)(3) | $51,394 | $0 | ESSENTIAL MEDICINES | |
| NAT'L INST OF ALLERGY & INFECTIOUS DISEASES (NIAID) | |||||||||
| 6610 ROCKLEDGE DR ROOM 2800 | BETHESDA | MD | 208926606 | 520858115 | GOV | $260,000 | $0 | ESSENTIAL MEDICINES | |
| NICHOLAS INST FOR ENVIRONMENTAL POLICY SOLUTIONS AT DUKE UNIVERSITY | |||||||||
| 2117 CAMPUS DR PO BOX 90335 | DURHAM | NC | 27708 | 560532129 | 501(C)(3) | $15,333 | $0 | PROGRAM INNOVATION | |
| ONA SYSTEMS INC | |||||||||
| 126 E 12TH ST SUITE 4A | NEW YORK | NY | 100035320 | 383940780 | OTHER | $256,923 | $0 | PROGRAM INNOVATION | |
| OPEN FUNCTION GROUP LLC | |||||||||
| 66 EUCLID AVE | HASTINGS ON HUDSON | NY | 10706 | OTHER | $62,200 | $0 | PROGRAM INNOVATION | ||
| OPENMRS INC | |||||||||
| 10425 COMMERCE DR STE 110 | CARMEL | IN | 460327643 | 455316647 | 501(C)(3) | $129,443 | $0 | PROGRAM INNOVATION | |
| PARTNERS IN HEALTH A NONPROFIT CORPORATION | |||||||||
| 800 BOYLSTON ST SUITE 300 | BOSTON | MA | 02199 | 043567502 | 501(C)(3) | $24,608 | $0 | PROGRAM INNOVATION | |
| PATHFINDER INTERNATIONAL | |||||||||
| 9 GALEN STREET SUITE 217 | WATERTOWN | MA | 02472 | 530235320 | 501(C)(3) | $104,629 | $0 | PROGRAM INNOVATION | |
| PHARMARON CPC INC | |||||||||
| 800 W BALTIMORE STREET 5TH FLOOR | BALTIMORE | MD | 21201 | 208419781 | OTHER | $76,832 | $0 | ESSENTIAL MEDICINES | |
| POPULATION COUNCIL | |||||||||
| ONE DAG HAMMERKJOLD PLAZA | NEW YORK | NY | 10017 | 131687001 | 501(C)(3) | $113,568 | $0 | PROGRAM INNOVATION | |
| POPULATION SERVICES INTERNATIONAL INC | |||||||||
| 1120 19TH ST NW STE 600 | WASHINGTON | DC | 20036 | 560942853 | 501(C)(3) | $640,025 | $0 | AMEE & PROGRAM INNOVATION | |
| REGENSTRIEF INSTITUTE INC | |||||||||
| 1101 W 10TH ST | INDIANAPOLIS | IN | 46202 | 300007730 | 501(C)(3) | $1,245,318 | $0 | PROGRAM INNOVATION | |
| ROSTROPOVICH-VISHNEVSKAYA FOUNDATION | |||||||||
| 1776 K STREET NW SUITE 700 | WASHINGTON | DC | 20006 | 521752473 | 501(C)(3) | $69,530 | $0 | ESSENTIAL MEDICINES | |
| RTI INTERNATIONAL | |||||||||
| PO BOX 12106 | DURHAM | NC | 277092106 | 560686338 | 501(C)(3) | $167,169 | $0 | PROGRAM INNOVATION | |
| SOLAR ELECTRIC LIGHT FUND | |||||||||
| 1612 K STREET NW SUITE 300 | WASHINGTON | DC | 20006 | 521701564 | 501(C)(3) | $32,052 | $0 | PROGRAM INNOVATION | |
| SYSTEMONE LLC | |||||||||
| 5 BRIDGE STREET | SHELBURNE FALLS | MA | 01370 | 461066795 | OTHER | $178,199 | $0 | AMEE | |
| TECHCHANGE INC | |||||||||
| 2001 13TH ST NW 2ND FLOOR | WASHINGTON | DC | 20009 | 273358772 | OTHER | $401,650 | $0 | PROGRAM INNOVATION | |
| TECHNICAL RESOURCES INTERNATIONAL INC (TRI) | |||||||||
| 6500 ROCK SPRING DR SUITE 650 | BETHESDA | MD | 20817 | 521122901 | OTHER | $14,582 | $0 | ESSENTIAL MEDICINES | |
| THE NATURE CONSERVANCY | |||||||||
| 4245 FAIRFAX DRIVE | ARLINGTON | VA | 22203 | 530242652 | 501(C)(3) | $28,818 | $0 | PROGRAM INNOVATION | |
| THE RECTOR AND VISITORS OF THE UNIVERSITY OF VIRGINIA (UVA) | |||||||||
| 1001 N EMMET ST | CHARLOTTESVILLE | VA | 22903 | 546001796 | 501(C)(3) | $66,037 | $0 | ESSENTIAL MEDICINES | |
| THE REGENTS OF THE UNIVERSITY OF CA SF | |||||||||
| UCSF OFFICE OF SPONSORED RES 3333 | SAN FRANCISCO | CA | 94118 | 946036493 | 501(C)(3) | $199,937 | $0 | PROGRAM INNOVATION | CALIFORNIA ST STE 315 |
| THE STATE UNIVERSITY OF NEW YORK | |||||||||
| 35 STATE STREET | ALBANY | NY | 122072826 | 141368361 | 501(C)(3) | $41,040 | $0 | ESSENTIAL MEDICINES | |
| TULANE UNIVERSITY | |||||||||
| 6823 ST CHARLES AVE | NEW ORLEANS | LA | 70112 | 720423889 | 501(C)(3) | $535,028 | $0 | ESSENTIAL MEDICINES & PROGRAM INNOVATION | |
| UNITED NATIONS FOUNDATION INC | |||||||||
| 1750 PENNSYLVANIA AVE NW STE 300 | WASHINGTON | DC | 20006 | 582368165 | 501(C)(3) | $178,680 | $0 | PROGRAM INNOVATION | |
| UNIVERSITY OF CALIFORNIA LOS ANGELES (UCLA) | |||||||||
| 10889 WILSHIRE BLVD SUITE 700 | LOS ANGELES | CA | 90095 | 956006143 | GOV | $276,086 | $0 | AFRICA | |
| UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC | |||||||||
| 310 E CAMPUS RD | ATHENS | GA | 30602 | 581353149 | 501(C)(3) | $71,437 | $0 | ESSENTIAL MEDICINES | |
| UNIVERSITY OF MARYLAND BALTIMORE | |||||||||
| BALTIMORE PO BOX 41428 | BALTIMORE | MD | 212036428 | 526002033 | GOV | $91,228 | $0 | ESSENTIAL MEDICINES | |
| UNIVERSITY OF MASSACHUSETTS | |||||||||
| MEDICAL SCHOOL 55 LAKE AVE NORTH | WORCESTER | MA | 01655 | 043167352 | GOV | $198,235 | $0 | PROGRAM INNOVATION | |
| UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | |||||||||
| CENTER FOR INFECTIOUS DISEASES | CHAPEL HILL | NC | 275993368 | 566001393 | 501(C)(3) | $618,814 | $0 | ESSENTIAL MEDICINES & PROGRAM INNOVATION | |
| UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | |||||||||
| 85 SOUTH PROSPECT STREET | BURLINGTON | VT | 05405 | 030179440 | 501(C)(3) | $313,359 | $0 | ESSENTIAL MEDICINES | |
| UNIVERSITY OF WASHINGTON (UW) | |||||||||
| GRANT CONTRACT ACCOUNTING 12455 | CHICAGO | IL | 60693 | 916001537 | 501(C)(3) | $1,500,176 | $0 | ESSENTIAL MEDICINES & PROGRAM INNOVATION | COLLECTIONS DRIVE |
| VILLAGEREACH | |||||||||
| 2900 EASTLAKE AVE E SUITE 230 | SEATTLE | WA | 981023012 | 912088484 | 501(C)(3) | $283,330 | $0 | AFRICA & PROGRAM INNOVATION | |
| VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY | |||||||||
| 300 TURNER ST NW SUITE 4200 | BLACKSBURG | VA | 24061 | 546001805 | GOV | $76,922 | $0 | ESSENTIAL MEDICINES | |
| VITAL STRATEGIES INC | |||||||||
| 100 BROADWAY 4TH FLOOR | NEW YORK | NY | 10005 | 223419667 | 501(C)(3) | $218,104 | $0 | PROGRAM INNOVATION | |
| VITAL WAVE INC | |||||||||
| 555 BRYANT STREET 226 | PALO ALTO | CA | 94301 | 203208079 | OTHER | $813,825 | $0 | PROGRAM INNOVATION | |
| WALTER REED ARMY INSTITUTE OF RESEARCH | |||||||||
| US TREASURY 503 ROBERT GRANT AVE | SILVER SPRING | MD | 20910 | 520664528 | GOV | $2,812,443 | $0 | ESSENTIAL MEDICINES | |
| WASHINGTON STATE UNIVERSITY | |||||||||
| 901 5TH AVE SUITE 2900 | SEATTLE | WA | 98164 | 916001108 | GOV | $310,104 | $0 | AFRICA | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 58 | Total501c3OrgCnt |
| Total Other Org | 20 | TotalOtherOrgCnt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | PATH HAS A SUBRECIPIENT POLICY AND PROCEDURES IN PLACE TO GUIDE THE WAY OUR PROJECT TEAMS MONITOR SUBRECIPIENTS. THIS INCLUDES BOTH FINANCIAL AND TECHNICAL MONITORING. PATH USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, AND OTHER MEANS TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD PROJECT STEWARDSHIP. THESE ACTIVITIES ALSO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS, AND THAT THE SUBRECIPIENT ACHIEVES PERFORMANCE GOALS. PATH HAS ESTABLISHED COMPREHENSIVE POLICIES AND PROCEDURES TO PROMOTE BEST BUSINESS PRACTICES AND ENSURE EFFICIENT AND EFFECTIVE INTERNAL CONTROL. THESE ARE COMBINED WITH AN INTERNAL AUDIT FUNCTION THROUGH WHICH PATH CONDUCTS AUDITS ON GRANT-FUNDED PROGRAMS TO ENSURE COMPLIANCE WITH REGULATORY REQUIREMENTS. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Idemnification Gross Up Pmts | Yes (X) | IdemnificationGrossUpPmtsInd |
| Housing Allowance Or Residence | Yes (X) | HousingAllowanceOrResidenceInd |
| Written Policy Ref T And E Expnss | Yes (1) | WrittenPolicyRefTAndEExpnssInd |
| Substantiation Required | Yes (1) | SubstantiationRequiredInd |
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Independent Consultant | Yes (X) | IndependentConsultantInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | Yes (1) | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | 0 | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | Yes (1) | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (16 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NIKOLAJ JESTED GILBERT MSC | ||||||||||||||
| PRESIDENT AND CEO | $455,096 | $0 | $135,000 | $0 | $1,800 | $0 | $34,200 | $0 | $9,530 | $0 | $635,626 | $0 | $0 | $0 |
| DAVID C KASLOW MD | ||||||||||||||
| CHIEF EXECUTIVE-ESSENTIAL MEDICINES | $406,234 | $0 | $0 | $0 | $1,950 | $0 | $34,200 | $0 | $33,763 | $0 | $476,147 | $0 | $0 | $0 |
| TRAD M HATTON MA MHS | ||||||||||||||
| COUNTRY DIRECTOR | $145,889 | $0 | $0 | $0 | $200,102 | $0 | $17,613 | $0 | $35,384 | $0 | $398,988 | $0 | $0 | $0 |
| ERICA JANE SESSLE MPHIL MPH | ||||||||||||||
| CHIEF OF STAFF (UNTIL 10/1/21) | $166,386 | $0 | $0 | $0 | $188,997 | $0 | $21,156 | $0 | $19,470 | $0 | $396,009 | $0 | $0 | $0 |
| JOHN O KONZ PHD | ||||||||||||||
| GLOBAL HEAD, INT. PTFL. & FIN. MGMT. | $329,574 | $0 | $0 | $0 | $840 | $0 | $32,831 | $0 | $32,063 | $0 | $395,308 | $0 | $0 | $0 |
| ASHLEY J BIRKETT PHD | ||||||||||||||
| GLOBAL HEAD, MALARIA VACCINES | $329,140 | $0 | $0 | $0 | $1,065 | $0 | $29,551 | $0 | $29,520 | $0 | $389,276 | $0 | $0 | $0 |
| KIMBERLY GREEN PHD | ||||||||||||||
| DIRECTOR, PRIMARY HEALTH CARE | $270,667 | $0 | $0 | $0 | $51,600 | $0 | $24,087 | $0 | $36,144 | $0 | $382,498 | $0 | $0 | $0 |
| JEFFREY D BERNSON MPH MPA | ||||||||||||||
| CHIEF EXECUTIVE-PROGRAM & INNOVATION | $322,840 | $0 | $0 | $0 | $0 | $0 | $32,628 | $0 | $26,256 | $0 | $381,724 | $0 | $0 | $0 |
| BRUCE LAMONT INNIS MD FIDSA | ||||||||||||||
| GLOBAL HEAD, RESPIRATORY INFECTIONS | $341,376 | $0 | $0 | $0 | $840 | $0 | $32,831 | $0 | -$1,842 | $0 | $373,205 | $0 | $0 | $0 |
| PHILIPPE GUINOT MBA | ||||||||||||||
| CHIEF OF BUSINESS, FIN. & OPERATIONS | $0 | $309,985 | $0 | $0 | $0 | $6,236 | $0 | $24,840 | $0 | $985 | $0 | $342,046 | $0 | $0 |
| CARLA ANNE COSTA SANDINE | ||||||||||||||
| CHIEF OF EXTERNAL AFFAIRS | $267,566 | $0 | $0 | $0 | $600 | $0 | $29,684 | $0 | $16,924 | $0 | $314,774 | $0 | $0 | $0 |
| MOLLI M BARNES | ||||||||||||||
| CHIEF PEOPLE OFFICER | $261,290 | $0 | $0 | $0 | $0 | $0 | $26,317 | $0 | $23,096 | $0 | $310,703 | $0 | $0 | $0 |
| SABRINA L POWERS JD | ||||||||||||||
| GENERAL COUNSEL | $263,164 | $0 | $0 | $0 | $2,025 | $0 | $31,728 | $0 | $13,004 | $0 | $309,921 | $0 | $0 | $0 |
| NANTHALILE C MUGALA MD MMED | ||||||||||||||
| CHIEF EXECUTIVE-AFRICA REGION | $208,499 | $0 | $0 | $0 | $80,180 | $0 | $0 | $0 | $0 | $0 | $288,679 | $0 | $0 | $0 |
| DAVID W FLEMING--SENIOR VP MD | ||||||||||||||
| OF PUBLIC HEALTH(UNTIL 2/11/21) | $42,434 | $0 | $0 | $0 | $198,768 | $0 | $8,176 | $0 | $1,865 | $0 | $251,243 | $0 | $0 | $0 |
| ELAINE L GIBBONS CFA | ||||||||||||||
| FRMR VP-GLOBAL ENGMT. (LEFT 2020) | $0 | $0 | $0 | $0 | $184,790 | $0 | $2,056 | $0 | $0 | $0 | $186,846 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail (3 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 1A | HOUSING ALLOWANCES & TAX INDEMNIFICATIONS ARE ONLY PROVIDED TO THOSE INDIVIDUALS WHO ARE EXPATRIATE EMPLOYEES. ALL BENEFIT PAYMENTS ARE MADE ACCORDING TO OUR EXPATRIATE POLICY. PART I, LINE 3: PATH ENGAGES WITH A CONSULTING FIRM TO REVIEW THE COMPENSATION FOR EACH OF THE SENIOR MANAGEMENT POSITIONS. PATH PROVIDES AN ANNUAL SALARY ADJUSTMENT EACH JANUARY BASED ON THE OVERALL LABOR MARKET MOVEMENT. |
| PART I, LINE 4A | LIST OF PERSONS IN FORM 990, PART VII, SECTION A WHO RECEIVED SEVERANCE PAYMENTS IN 2021: - DAVID W. FLEMING $172,266 - ELAINE L. GIBBONS $143,508 - JERRY KUO $99,570 - ERICA JANE SESSLE $170,055 |
| PART I, LINE 7 | BONUS COMPENSATION HAS BEEN REFLECTED IN PART II, COLUMN (B)(II). |
Schedule M IRS990ScheduleM
Securities Publicly Traded SecuritiesPubliclyTradedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 14 | ContributionCnt |
| Noncash Contributions Rpt F990 | $9,567 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | FMV | MethodOfDeterminingRevenuesTxt |
Other Non Cash Contri Table OtherNonCashContriTableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Desc | SOFTWARE/SUPP. | Desc |
| Contribution | 5 | ContributionCnt |
| Noncash Contributions Rpt F990 | $3,088,330 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | COST | MethodOfDeterminingRevenuesTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form8283 Received | 0 | Form8283ReceivedCnt |
| Any Property That Must Be Held | 0 | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | Yes (1) | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | 0 | ThirdPartiesUsedInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, COLUMN (B): | FormAndLineReferenceDesc |
| Explanation | THIS COLUMN REFLECTS THE NUMBER OF CONTRIBUTIONS. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (11 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART III, LINE 1, DESCRIPTION OF ORGANIZATION MISSION: | PATH IS A GLOBAL NONPROFIT DEDICATED TO ACHIEVING HEALTH EQUITY. WITH MORE THAN 40 YEARS OF EXPERIENCE FORGING MULTISECTOR PARTNERSHIPS, AND WITH EXPERTISE IN SCIENCE, ECONOMICS, TECHNOLOGY, ADVOCACY, AND DOZENS OF OTHER SPECIALTIES, PATH DEVELOPS AND SCALES UP INNOVATIVE SOLUTIONS TO THE WORLD'S MOST PRESSING HEALTH CHALLENGES. |
| FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE: | (1) IMPROVING ACCESS TO MEDICAL OXYGEN AND RELATED RESPIRATORY CARE PRODUCTS IN LMICS. AS PART OF THAT WORK, WE SUPPORTED OUR GOVERNMENT PARTNERS IN THE DEVELOPMENT AND EXECUTION OF COMPREHENSIVE RESPIRATORY CARE PLANS TO MEET THE DEMANDS OF COVID-19. BEYOND THE PANDEMIC RESPONSE, WE ALSO HELPED PRIORITIZE AND IMPROVE ACCESS TO OXYGEN THERAPY AND OTHER ESSENTIAL RESPIRATORY CARE EQUIPMENT AS AN INTEGRAL PART OF NATIONAL AND GLOBAL HEALTH SYSTEMS STRENGTHENING. IN INDIA, KENYA, SENEGAL, AND TANZANIA, WE ADVANCED ACCESS TO AFFORDABLE AND APPROPRIATE TOOLS SUCH AS PULSE OXIMETRY AND ELECTRONIC CLINICAL DECISION-SUPPORT ALGORITHMS TO HELP HEALTH CARE WORKERS IDENTIFY CRITICALLY ILL CHILDREN AND REFER THEM FOR TREATMENT WITHOUT DELAY. (2) SUPPORTING INTRODUCTION AND SCALE-UP OF MALARIA HEALTH PRODUCTS. THROUGH OUR ROLE IN THE PARTNERSHIP FOR VIVAX ELIMINATION, WE CONTINUED TO FOSTER ACCESS TO CRITICAL MALARIA DRUGS AND DIAGNOSTICS FOR ADULTS AND CHILDREN ACROSS 15 MALARIA-ENDEMIC COUNTRIES. EPIDEMIC PREPAREDNESS AND RESPONSE PATH'S EPIDEMIC PREPAREDNESS AND RESPONSE TEAM CONTINUED TO INNOVATE FOR THE PREVENTION, DETECTION, AND CONTROL OF INFECTIOUS DISEASE OUTBREAKS. UNDER THE USAID DISCOVERY & EXPLORATION OF EMERGING PATHOGENS - VIRAL ZOONOSES PROJECT, THE TEAM SUPPORTED GLOBAL DATA MANAGEMENT AND SHARING AND LED PROJECT START-UP IN SENEGAL AND VIETNAM. THE TEAM WORKED AS A MAJOR SUBGRANTEE ON THE USAID INFECTIOUS DISEASE DETECTION AND SURVEILLANCE (IDDS) PROJECT AND LED IN SENEGAL, TANZANIA, UGANDA, AND VIETNAM. IN THESE COUNTRIES, OUR CROSS-ORGANIZATIONAL IMPACT TEAM ALSO SUPPORTED COVID-19 OUTBREAK RESPONSE ACTIVITIES, WHILE REMAINING AT THE FOREFRONT OF ANTIMICROBIAL RESISTANCE AND GENOMIC SURVEILLANCE IN VIETNAM, IN PARTICULAR. WITH SUPPORT FROM THE U.S. CDC, PATH WORKED WITH NATIONAL LEADERS IN MYANMAR, SENEGAL, TANZANIA, AND VIETNAM TO BUILD CAPACITY FOR EPIDEMIC PREPAREDNESS AND RESPONSE. OTHER EFFORTS INCLUDED STRENGTHENING ELECTRONIC HEALTH INFORMATION SYSTEMS, ADVANCING DIAGNOSTIC NETWORK CAPABILITIES, AND LINKING THIS WORK WITH THE DEVELOPMENT OF NEW DIAGNOSTICS, VACCINES, AND DATA TOOLS. MALARIA AND NEGLECTED TROPICAL DISEASES PATH PARTNERS WITH GOVERNMENTS, THE PRIVATE SECTOR, AND FUNDERS AROUND THE GLOBE TO BRING THE WORLD CLOSER TO MALARIA ERADICATION. OUR MALARIA AND NEGLECTED TROPICAL DISEASES PROGRAM INCLUDES MORE THAN 100 PATH STAFF MEMBERS IN TEN COUNTRIES. OUR STRATEGY INCLUDES OPTIMIZING THE DELIVERY OF CURRENT TOOLS AND APPROACHES TO ENSURE THEY REACH THE PEOPLE WHO NEED THEM, DESIGNING NEW STRATEGIES AND DEVELOPING NEXT-GENERATION TOOLS TO OVERCOME EMERGING CHALLENGES, AND CREATING INNOVATIVE PARTNERSHIPS AND FUNDING MODELS TO ENSURE OUR PROGRAMS ARE SUSTAINABLE AND EFFECTIVE. IN 2021, OUR MALARIA CONTROL AND ELIMINATION PARTNERSHIP IN AFRICA (MACEPA) PROGRAM CONTINUED TO SUPPORT THE GOVERNMENTS OF ETHIOPIA, SENEGAL, AND ZAMBIA TOWARD THEIR MALARIA ELIMINATION GOALS. FOR INSTANCE, MACEPA PROVIDED MATHEMATICAL MODELING AND DATA ANALYTICS SUPPORT, INCLUDING ESTIMATING THE CATCHMENT POPULATION OF EACH HEALTH FACILITY IN ZAMBIA AND USING HUMAN MIGRATION DATA TO CAPTURE POPULATION FLOW AT THE DISTRICT LEVEL IN ETHIOPIA. MACEPA ALSO CONDUCTED EXPLORATORY ACTIVITIES IN THE DEMOCRATIC REPUBLIC OF THE CONGO (DRC) AND NIGERIA (E.G., ANALYSES OF CURRENT MALARIA SURVEILLANCE SYSTEMS) TO INFORM TECHNICAL ASSISTANCE NEEDS AND RECOMMENDATIONS FOR THOSE GEOGRAPHIES. THE PAMO PLUS PROJECT, FUNDED BY THE U.S. PRESIDENT'S MALARIA INITIATIVE (PMI), PROVIDED TECHNICAL AND MATERIAL ASSISTANCE TO THE ZAMBIA MINISTRY OF HEALTH (MOH) IN MALARIA CASE MANAGEMENT, MALARIA IN PREGNANCY, SOCIAL BEHAVIOR CHANGE, DISEASE SURVEILLANCE, AND DATA MANAGEMENT AND USE. WORK IN 2021 INVOLVED MENTORING HEALTH WORKERS IN THE PROJECT'S FOUR FOCUS PROVINCES ON ADHERENCE TO MALARIA CASE MANAGEMENT STANDARDS AS WELL AS TRAINING, DEPLOYING, AND SUPPORTING COMMUNITY HEALTH WORKERS WHO TEST AND TREAT MALARIA AT THE COMMUNITY LEVEL. ADDITIONALLY, PAMO PLUS WORKED WITH THE ZAMBIA NURSING AND MIDWIFERY COUNCIL TO INTEGRATE MALARIA IN PREGNANCY TRAINING INTO THE NURSING COLLEGE CURRICULUM, AND TRAINED ANTENATAL CARE PROVIDERS AND SAFE MOTHERHOOD ACTION GROUP MEMBERS ON THE MALARIA IN PREGNANCY GUIDELINES. PAMO PLUS SUPPORTED THE DEVELOPMENT OF COMMUNITY ENGAGEMENT PLANS, ORIENTED COMMUNITY CHANGE AGENTS, CONDUCTED DATA QUALITY AUDITS, AND TRAINED MOH STAFF IN DATA MANAGEMENT AND MENTORSHIP. PAMO PLUS CONTINUED IMPLEMENTING A MALARIA PRE-ELIMINATION PROGRAM, CONDUCTING RESEARCH IN LOW-BURDEN DISTRICTS OF EASTERN PROVINCE, ZAMBIA. IN 2021, PATH CONTINUED TO EVALUATE NEW VECTOR CONTROL TOOLS WITH OUR PARTNERS UNDER PMI VECTORLINK, USAID'S FLAGSHIP MALARIA VECTOR CONTROL PROJECT. SIMILARLY, UNDER THE NEW NETS PROJECT FUNDED BY UNITAID AND THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA (THE GLOBAL FUND), WE HELPED GENERATE EVIDENCE FOR THE ADOPTION OF BEDNETS EFFECTIVE AGAINST PYRETHROID-RESISTANT MOSQUITOES. IN ZAMBIA, PATH LED THE DESIGN AND IMPLEMENTATION OF LABORATORY AND FIELD ACTIVITIES TO TEST ANOTHER NEW TOOL FOR MALARIA VECTOR CONTROL, THE ATTRACTIVE TARGETED SUGAR BAIT (ATSB). WE COORDINATED PARTNERS WORKING ON ATSB RESEARCH IN KENYA, MALI, AND ZAMBIA, TOGETHER WITH ISRAEL-BASED MANUFACTURER WESTHAM LTD. AND U.K.-BASED FUNDER INNOVATIVE VECTOR CONTROL CONSORTIUM. PATH ALSO LED A USAID INITIATIVE TO SUPPORT MALARIA OPERATIONAL RESEARCH AND PROGRAM EVALUATION. UNDER THE PMI INSIGHTS PROJECT, PATH COORDINATED THE WORK OF SEVERAL PARTNERS TO STRENGTHEN NATIONAL POLICIES, STRATEGIES, AND GUIDELINES FOR MALARIA CONTROL AND ELIMINATION. IN SENEGAL AND THE GAMBIA, PATH CONTINUED TO INTEGRATE MALARIA INTO THE SCOPE OF NATIONAL EMERGENCY OPERATIONS CENTERS (EOCS). IN SENEGAL, WE SUPPORTED THE MOH TO CREATE AND RESOURCE REGIONAL EOC-MALARIA UNITS. WITH A REGIONAL PRESENCE, THE EOC CAN MORE RAPIDLY RESPOND TO POTENTIAL PUBLIC HEALTH THREATS. THIS WORK HAS STRENGTHENED CROSS-BORDER COLLABORATION BETWEEN THE GAMBIA AND SENEGAL ON EMERGENCY PREPAREDNESS AND RESPONSE AND MALARIA INTERVENTIONS. PATH'S LABORATORY TEAM AT THE NATIONAL MALARIA ELIMINATION CENTER IN LUSAKA, ZAMBIA - A TEAM TASKED WITH GENOTYPING PLASMODIUM PARASITES TO LOOK FOR MARKERS OF RESISTANCE TO COMMON MALARIA TREATMENTS - ALSO APPLIED THEIR EXPERTISE TO SARS-COV-2. IN 2021, THEY WORKED WITH THE UNIVERSITY OF ZAMBIA'S SCHOOL OF VETERINARY MEDICINE TO SEQUENCE INFECTIONS AND MAP THE RISE AND FALL OF DIFFERENT COVID-19 VARIANTS. THE TEAM RECEIVED FUNDING TO EXPAND THEIR FOCUS FROM GENERATING DATA TO STRENGTHENING THE SEQUENCING SKILLS WITHIN THE ZAMBIAN GOVERNMENT. THE VIVACTION PROJECT WORKS TO CATALYZE ADOPTION AND EVENTUAL SCALE-UP OF PLASMODIUM VIVAX TOOLS. IN ETHIOPIA, PATH IS STUDYING WHETHER IT IS OPERATIONALLY FEASIBLE TO PROVIDE OPTIMIZED RADICAL CURE TREATMENT TO P. VIVAX PATIENTS WHO ARE ELIGIBLE BASED ON TREATMENT GUIDELINES. IN 2021, PATH HELD MEETINGS WITH LOCAL PARTNER ARMAUER HANSEN RESEARCH INSTITUTE TO DISCUSS PROJECT ACTIVITIES. IN INDIA, PATH CONTINUED TO PROVIDE STRATEGIC TECHNICAL ASSISTANCE IN THE STATE OF UTTAR PRADESH, SUPPORTING THE NATIONAL VECTOR BORNE DISEASE CONTROL PROGRAM TO ADDRESS DENGUE AND MALARIA THROUGH SKILLS STRENGTHENING, OUTBREAK INVESTIGATION, AND DATA MANAGEMENT. PATH PROVIDED TECHNICAL SUPPORT FOR SAFE AND SUCCESSFUL MASS DRUG ADMINISTRATION CAMPAIGNS AS WELL AS MORBIDITY MANAGEMENT AND DISABILITY PREVENTION SERVICES ACROSS 50 LYMPHATIC FILARIASIS-ENDEMIC DISTRICTS. IN THE STATE OF BIHAR, PATH SUPPORTED IMPLEMENTATION OF A JAPANESE ENCEPHALITIS VACCINATION CAMPAIGN. EARLY CHILDHOOD DEVELOPMENT ACTION NETWORK IN 2021, THE EARLY CHILDHOOD DEVELOPMENT ACTION NETWORK (ECDAN), HOSTED BY PATH, CONTINUED TO ADVOCATE FOR YOUNG CHILDREN AND THEIR CAREGIVERS. ECDAN SUPPORTED AND FACILITATED SEVERAL COLLABORATIVE INITIATIVES, INCLUDING LAUNCH OF THE GLOBAL CHILDCARE CAMPAIGN AND - WITH OUR PARTNERS, THE WORLD HEALTH ORGANIZATION (WHO), UNICEF, PARTNERSHIP FOR LIFELONG HEALTH, AND GLOBAL PARTNERSHIP TO END VIOLENCE AGAINST CHILDREN - LAUNCH OF THE GLOBAL INITIATIVE TO SUPPORT PARENTS. ECDAN CONNECTED AND ALIGNED THE GLOBAL COMMUNITY THROUGH CALLS TO ACTION, JOINT STATEMENTS, AND COMMUNITIES OF PRACTICE AND ACCELERATED LEARNING AND KNOWLEDGE EXCHANGE THROUGH WEBINARS AND TWO PLATFORMS: ECD CONNECT AND ECD KNOWLEDGE GATEWAY. ECDAN FINALIZED THREE COUNTRY PILOTS TO TEST THE "COST OF INACTION" METHODOLOGY WITH UNICEF IN BULGARIA AND MADAGASCAR AND WITH THE UNIVERSITY OF SAO PAULO IN BRAZIL. ECDAN ALSO WELCOMED OUR FIRST COHORT OF KNOWLEDGE FELLOWS. FIVE FELLOWS (FROM COLOMBIA, THE PHILIPPINES, SPAIN, UNITED STATES, AND ZAMBIA) COMPLETED THE PROGRAM, WORKING WITH A MENTOR TO DESIGN AND FINALIZE A KNOWLEDGE PRODUCT. |
| FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE: | PRIMARY HEALTH CARE PATH'S PRIMARY HEALTH CARE (PHC) DEPARTMENT EMPLOYS A COMPREHENSIVE, ONE HEALTH, PEOPLE- AND COMMUNITY-CENTERED PHC MODEL THAT ADDRESSES BROADER DETERMINANTS OF HEALTH (E.G., SOCIAL, ECONOMIC, ENVIRONMENTAL). WE FOCUS ON INNOVATIVE, EVIDENCE-BASED TOOLS AND APPROACHES TO MEET PEOPLE'S NEEDS AND PREFERENCES ACROSS THEIR LIFETIME. PHC AT PATH IS COMPOSED OF SIX TEAMS, DESCRIBED BELOW. MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION TOGETHER WITH PARTNERS AROUND THE WORLD, PATH'S MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION (MNCHN) TEAM DEVELOPS, ADAPTS, AND SCALES UP TECHNOLOGIES AND SYSTEMS TO REDUCE ILLNESS AND DEATH AMONG MOTHERS AND CHILDREN AND GIVE CHILDREN THE BEST POSSIBLE START IN LIFE. TO ENSURE THAT ALL INFANTS HAVE ACCESS TO HUMAN MILK, PATH FOCUSES ON BREASTFEEDING PROMOTION, PROVISION OF SPECIALIZED LACTATION SUPPORT FOR MOTHERS OF SMALL AND SICK NEWBORNS, AVAILABILITY OF SAFE DONOR MILK THROUGH LOCAL HUMAN MILK BANKS, AND UPTAKE AND USE OF GLOBAL STANDARDS FOR HUMAN MILK BANKING. USING HUMAN-CENTERED DESIGN, WE CONTINUED CREATING A DIGITAL ADAPTATION KIT FOR OPTIMAL NEWBORN FEEDING AND THE PROVISION OF LACTATION SUPPORT, WHICH IS BEING DEVELOPED IN KENYA AS A GLOBAL GOOD FOR ALL SETTINGS. PATH CONTINUED SUPPORTING ARIADNE LABS AS A SUBJECT MATTER EXPERT AND PERFORMED A FEASIBILITY ASSESSMENT IN INDIA, MALAWI, AND TANZANIA ON THE USE OF DONOR HUMAN MILK FOR LOW-BIRTHWEIGHT INFANTS. THESE FINDINGS ARE BEING DISSEMINATED GLOBALLY AND THROUGH MULTIPLE PEER-REVIEWED PUBLICATIONS. IN GHANA, PATH IS LEADING A FOUR-YEAR EFFORT, ADVANCED NEWBORN CARE IN GHANA: BEYOND MAKING EVERY BABY COUNT INITIATIVE (MEBCI 2.0), TO REDUCE PERINATAL MORTALITY IN FOUR HIGH-VOLUME REFERRAL HOSPITALS. IN 2021, MEBCI 2.0 ENGAGED WITH THE GHANA HEALTH SERVICE TO OPERATIONALIZE ITS NEWBORN ACTION PLAN, MOBILIZE REGIONAL STAKEHOLDERS AND RESOURCES, AND DRIVE ADVOCACY AND POLICY ACTION. THROUGH THE NEOLENS PROJECT, PATH DOCUMENTED COUNTRY-LEVEL JOURNEYS IN ESTABLISHING IN-PATIENT CARE FOR SMALL AND SICK NEWBORNS IN LOW-RESOURCE SETTINGS. TO SHOWCASE LESSONS LEARNED IN ETHIOPIA, INDIA, MALAWI, AND RWANDA, WE CREATED CASE STUDIES FOR EACH COUNTRY AND PARTNERED WITH MASS DESIGN GROUP TO DEVELOP AN INTERACTIVE, VIRTUAL EXPERIENCE. FOLLOWING A PATH PROJECT THAT DOCUMENTED UPTAKE OF 14 KEY MNCHN ASSETS IN 81 COUNTDOWN TO 2030 COUNTRIES, IN 2021 PATH CONDUCTED A SUBNATIONAL INQUIRY IN FIVE FOCUS COUNTRIES ON THE INHERENT BARRIERS AND ENABLERS TO SCALE-UP OF THESE COMMODITIES. WE DEVELOPED COMPLEMENTARY INTERACTIVE DASHBOARDS TO PROVIDE THE DATA IN A USER-FRIENDLY INTERFACE. IN COLLABORATION WITH THE GHANA HEALTH SERVICE AND WITH FUNDING FROM THE PFIZER FOUNDATION, PATH INITIATED THE INTEGRATED ANTENATAL CARE PROJECT IN THE BONO EAST REGION OF GHANA. THE PROJECT AIMS TO AVERT INFECTIOUS DISEASE MORTALITY AND MORBIDITY IN NEONATES AND MOTHERS BY IMPLEMENTING AN IMPROVED, COMPREHENSIVE INFECTIOUS DISEASE SCREENING PROGRAM DURING PREGNANCY. ALSO IN 2021, MNCHN STAFF SERVED GLOBALLY IN LEADERSHIP ROLES RELATED TO COVID-19 AND THE PROTECTION OF WOMEN AND CHILDREN. WE PARTICIPATED IN GLOBAL TECHNICAL WORKING GROUPS, PRESENTED (MOSTLY VIRTUALLY) AT KEY GLOBAL AND NATIONAL MEETINGS, AND AUTHORED AND CONTRIBUTED TO HIGH-PROFILE PEER-REVIEWED JOURNAL ARTICLES, BOOK CHAPTERS, GLOBAL REPORTS, AND SYSTEMATIC REVIEWS. THESE EFFORTS ADVANCED THINKING ON BROAD, EFFECTIVE SOLUTIONS TO THE MOST PRESSING CHALLENGES IN MNCHN. RECOGNIZING THAT NUTRITION IS AFFECTED BY A VARIETY OF ECONOMIC AND ENVIRONMENTAL FACTORS, PATH'S NUTRITION TEAM DRIVES NOVEL APPROACHES TO ADDRESS THE MASSIVE BURDEN OF MALNUTRITION IN COMMUNITIES AROUND THE WORLD. TOGETHER WITH PATH'S CLIMATE CHANGE COMMUNITY OF PRACTICE, PATH'S NUTRITION TEAM CONTINUED TO ADVOCATE FOR SUSTAINABLE CLIMATE-FRIENDLY ALTERNATIVES, SUCH AS CULTURED PROTEINS AND EDIBLE INSECTS. AS A REFLECTION OF OUR EXPERTISE, PATH LEADS THE BIOMARKER COLLECTION AND ANALYSIS COMPONENTS OF THE DEMOGRAPHIC HEALTH SURVEY CONDUCTED IN COUNTRIES AROUND THE WORLD. FINALLY, PATH CONTINUED OUR WORK ON THE BRIDGE COLLABORATIVE, A TRAILBLAZING, CROSS-DISCIPLINARY EFFORT OF MORE THAN 150 LEADING TECHNICAL EXPERTS FROM THE HEALTH, DEVELOPMENT, AND ENVIRONMENTAL SECTORS TO ADDRESS HUMAN AND PLANETARY HEALTH. EARLY CHILDHOOD DEVELOPMENT IN 2021, PATH CONTINUED TO EXPAND OUR GLOBAL AND NATIONAL LEADERSHIP IN EARLY CHILDHOOD DEVELOPMENT (ECD). FOR EXAMPLE, WITH PATH SUPPORT, THE GOVERNMENTS OF ETHIOPIA, KENYA, AND MOZAMBIQUE CONTINUED TO SCALE UP ECD SERVICE PROVISION AS AN ESSENTIAL COMPONENT OF BASIC HEALTH CARE AND INTRODUCED INTEGRATED ECD SERVICE DELIVERY INTO ADDITIONAL SUBNATIONAL GEOGRAPHIES. THIS PIONEERING WORK CENTERS AROUND BUILDING AN ENABLING LEADERSHIP AND POLICY ENVIRONMENT WHILE STRENGTHENING THE CAPACITY OF HEALTH SYSTEMS AND HEALTH SERVICE PROVIDERS. WITH A CONSTELLATION OF PARTNERS, PATH FACILITATED COLLECTIVE ACTION ACROSS MULTIPLE SECTORS AT NATIONAL AND SUBNATIONAL LEVELS TO PROMOTE ECD THROUGH ENHANCED PLANNING, COORDINATION, AND RESOURCING. HEALTH SYSTEMS THE HEALTH SYSTEMS TEAM SERVES AS AN ORGANIZING MECHANISM FOR PATH'S PROJECTS AND INITIATIVES THAT STRENGTHEN HEALTH SYSTEMS. BOTH WITHIN PATH AND IN COLLABORATION WITH EXTERNAL PARTNERS, THE TEAM LEADS COMPLEX EVALUATIONS OF HEALTH PROGRAMS, ENGAGES IN IMPLEMENTATION SCIENCE RESEARCH, FACILITATES INTERVENTION SCALE-UP, AND IMPROVES DATA QUALITY AND USE FOR DECISION-MAKING. IN 2021, MAJOR ACTIVITIES INCLUDED (1) COMPLETION OF A FOUR-YEAR PROSPECTIVE EVALUATION OF THE GLOBAL FUND'S INVESTMENTS IN THE DRC, GUATEMALA, SENEGAL, AND UGANDA; (2) LEADING MONITORING, EVALUATION, AND LEARNING WITHIN USAID'S MOMENTUM ROUTINE IMMUNIZATION TRANSFORMATION AND EQUITY (M-RITE) PORTFOLIO ACROSS SEVERAL COUNTRIES IN AFRICA AND SOUTHEAST ASIA; AND (3) EVALUATION OF AN INNOVATION TO INCREASE HIV PRE-EXPOSURE PROPHYLAXIS UPTAKE AMONG ADOLESCENT GIRLS AND YOUNG WOMEN IN ZIMBABWE. HIV, TUBERCULOSIS, AND VIRAL HEPATITIS AS COVID-19 CONTINUED TO DISRUPT ACCESS TO ESSENTIAL HEALTH SERVICES, PATH'S HIV, TUBERCULOSIS (TB), AND VIRAL HEPATITIS TEAM FOCUSED ON ADVANCING PERSON-CENTERED HEALTH CARE ACROSS AFRICA, CENTRAL ASIA, AND SOUTHEAST ASIA FOR GENERAL, KEY, AND PRIORITY POPULATIONS. METHODS INCLUDED PROMOTING INTEGRATED SERVICE DELIVERY MODELS, ACCELERATING SELF-CARE INITIATIVES, AND LEVERAGING DIGITAL HEALTH TOOLS TO ENSURE EQUITABLE AND HIGH-QUALITY ACCESS TO HEALTH SERVICES. PATH, WITH FUNDING FROM UNITAID THROUGH THE STAR-III PROJECT, CONTINUED TO ACCELERATE ACCESS TO HIV SELF-TESTING (HIVST) IN INDIA, INDONESIA, AND UGANDA BY CONDUCTING ASSESSMENTS TO INFORM DEVELOPMENT OF NEW HIVST DISTRIBUTION MODELS AND NATIONAL POLICIES AND GUIDELINES. IN 2021, THE PROJECT SUPPORTED THE DISTRIBUTION OF MORE THAN 150,000 HIVST KITS AND TRAINED MORE THAN 750 PROVIDERS ON HIVST SERVICES. PATH ALSO RECEIVED FUNDING TO ADVANCE SELF-TESTING FOR HEPATITIS C IN INDIA AND VIETNAM AND SELF-TESTING FOR COVID-19 IN BRAZIL, INDIA, SOUTH AFRICA, AND UGANDA, WITH THIS YEAR'S EFFORTS FOCUSED ON ORIENTING STAKEHOLDERS AND PREPARING FOR IMPLEMENTATION. AS A PARTNER ON THE UNITAID-FUNDED ADHERENCE SUPPORT COALITION TO END TB PROJECT, PATH WORKED TO ESTABLISH A GLOBAL MARKET FOR DIGITAL ADHERENCE TECHNOLOGIES (DATS). WE IMPLEMENTED RESEARCH IN UKRAINE ON THE USE OF DATS AND SUCCESSFULLY ADVOCATED WITH THE UKRAINIAN GOVERNMENT FOR SCALE-UP OF DATS DURING WAR AND AMONG DISPLACED PERSONS. IN PARTNERSHIP WITH THE TB ALLIANCE, PATH WORKED TO ADVANCE A SHORTER TREATMENT (BEDAQUILINE, PRETOMANID, AND LINEZOLID, KNOWN AS BPAL) FOR MULTIDRUG-RESISTANT TB, DEVELOPING A ROAD MAP TO INTRODUCE BPAL IN PERU AND UKRAINE AS WELL AS FACILITATING A COSTING STUDY OF BPAL IN UKRAINE. IN THE DRC, UNDER THE USAID-FUNDED INTEGRATED HIV/AIDS PROJECT IN HAUT-KATANGA (IHAP-HK), PATH TESTED AND EXPANDED PERSON-CENTERED APPROACHES FOR ENHANCED CARE, TREATMENT SUPPORT, AND VIRAL LOAD MONITORING. THE PROJECT CO-CREATED AN ELECTRONIC CLIENT FEEDBACK SYSTEM WITH FACILITY PROVIDERS AND ASSOCIATIONS OF PEOPLE LIVING WITH HIV (PLHIV) AND THEN TESTED THE SYSTEM AT SIX FACILITIES. IMPLEMENTATIONS BASED ON THE FEEDBACK RESULTED IN SHORTER WAIT TIMES FOR CLIENTS AND FEWER INSTANCES OF STIGMA AND DISCRIMINATION. IHAP-HK ALSO CO-ADAPTED, WITH ADOLESCENTS AND YOUNG PEOPLE, KENYA'S OPERATION TRIPLE ZERO APPROACH FOR THE DRC CONTEXT. THIS LED TO THE CREATION OF ADDITIONAL COMMUNITY SUPPORT GROUPS FOR CHILDREN, ADOLESCENTS, AND YOUNG PEOPLE FOCUSED ON PROMOTING ADHERENCE TO TREATMENT AND CLINICAL APPOINTMENTS, WITH THE GOAL OF VIRAL SUPPRESSION. THE PROJECT ALSO TESTED COLLABORATIVE CASE MANAGEMENT AMONG HEALTH WORKERS, PEER EDUCATORS, AND CASE MANAGERS FOR CHILDREN LIVING WITH HIV TO PROVIDE ENHANCED ADHERENCE SUPPORT SERVICES, AGAIN TO HELP ACHIEVE VIRAL SUPPRESSION. |
| FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE: | IN WESTERN KENYA, PATH SUCCESSFULLY CLOSED OUT THE PEPFAR-FUNDED AFYA ZIWANI PROJECT. OVER THE PROJECT LIFETIME, 1,586,802 PEOPLE WERE TESTED FOR HIV, OF WHICH 25,569 WERE DIAGNOSED WITH HIV AND LINKED TO CARE AND TREATMENT. IN MID-2021, PATH TRANSITIONED THE PROGRAMMING TO TWO NEW INITIATIVES: (1) A COMPREHENSIVE PACKAGE OF HEALTH, SOCIAL, AND ECONOMIC STRENGTHENING SERVICES FOR CHILDREN, ADOLESCENTS, AND YOUNG PEOPLE THROUGH THE PEPFAR-FUNDED NURU YA MTOTO PROJECT, FOR WHICH PATH IS PRIME; AND (2) HIGH-QUALITY CLINICAL HIV AND TB/HIV SERVICES FOR PEOPLE LIVING WITH OR AT RISK OF HIV THROUGH THE PEPFAR-FUNDED BORESHA JAMII PROJECT, FOR WHICH PATH IS A KEY SUBPARTNER LEADING THE CLINICAL WORK. PATH ALSO LED THE CHAK A CHAKA PROJECT, WHICH STRENGTHENS ECONOMIC SKILLS AMONG YOUNG WOMEN IN KISUMU, HOMA BAY, AND MIGORI COUNTIES TO REDUCE HIV RISK AND VULNERABILITY. IN 2021, PATH HELPED 1,225 YOUNG WOMEN BUILD SAVINGS AND ENTREPRENEURIAL SKILLS THROUGH ACCESS TO BUSINESS DEVELOPMENT TRAININGS AND INSURANCE FUNDS. IN INDIA, THROUGH THE U.S. CDC-FUNDED STRENGTHENING STRATEGIC INFORMATION MANAGEMENT SYSTEMS PROJECT, PATH CONTINUED TO SUPPORT THE NATIONAL AIDS CONTROL PROGRAM AT THE STATE AND DISTRICT LEVEL IN MUMBAI AND ANDHRA PRADESH AS WELL AS NATIONALLY TO FURTHER STREAMLINE DATA REPORTING SYSTEMS AND ENHANCE DATA USE FOR PROGRAM IMPROVEMENT AND PLANNING. AMONG OTHER ACTIVITIES, WE CREATED SITE-LEVEL SYSTEMS TO IMPROVE FOLLOW-UP WITH CLIENTS, DEPLOYED A MONTHLY DISTRICT-LEVEL PLANNING PROCESS IN ANDHRA PRADESH TO IMPROVE HIV TESTING AND LINKAGES TO SERVICE, AND CREATED NATIONAL-LEVEL DASHBOARDS TO BETTER MONITOR HIV PROGRAM PERFORMANCE AGAINST EPIDEMIC CONTROL INDICATORS. IN SUPPORT OF TB PROGRAMMING IN INDIA, PATH INTRODUCED ARTIFICIAL INTELLIGENCE TO STREAMLINE CHEST X-RAY READINGS, ENABLING QUICKER DIAGNOSIS AND INITIATION ON TREATMENT. WITH SUPPORT FROM USAID, PATH FACILITATED A NEEDS ASSESSMENT FOR TECHNICAL SUPPORT UNITS TO FOSTER LOCAL PRIVATE-SECTOR ENGAGEMENT ACROSS FIVE INDIAN STATES. PATH ALSO SUPPORTED REVISIONS AND UPDATES TO TB CONTROL STANDARDS IN PARTNERSHIP WITH WHO AND THE NATIONAL TB PROGRAM. IN ZAMBIA, PATH CONTINUED TO IMPLEMENT THE USAID-FUNDED ERADICATE TB PROJECT, WHICH SCREENED 1,967,914 INDIVIDUALS FOR SYMPTOMS OF TB, AMONG WHOM 223,337 (11%) WERE PRESUMED TO HAVE TB. SAMPLES FROM 200,899 (90%) OF THOSE WERE THEN TESTED IN THE LABORATORY, RESULTING IN 9,872 (5%) CONFIRMED TB CASES. OF THESE, 9,521 (96%) WERE SUCCESSFULLY INITIATED ON TREATMENT. THE PROJECT ALSO STRENGTHENED THE LABORATORY NETWORK TO MORE EFFICIENTLY AND EFFECTIVELY DIAGNOSE AND MONITOR PEOPLE WITH TB. AN EXTERNAL QUALITY ASSESSMENT SHOWED THAT 90% OF HEALTH FACILITY LABORATORIES ACHIEVED 95% CORRECT RESULTS. THE PROJECT CONTINUED TO TRAIN FRONTLINE HEALTH CARE WORKERS IN THE SIX SUPPORTED PROVINCES ON CHILDHOOD TB DETECTION AND DRUG-RESISTANT TB CASE MANAGEMENT. IN TANZANIA, THE USAID-FUNDED IDDS PROJECT SUPPORTED KEY FUNCTIONS AT THE CENTRAL TB REFERENCE LABORATORY, FACILITATED REPORTING FROM SITES USING THE GENEXPERT PLATFORM, COMPLETED AN ASSESSMENT OF THE TB DIAGNOSTIC NETWORK, AND PREPARED FOR INTRODUCTION OF NEW DIAGNOSTIC METHODS. THROUGH THIS PROJECT IN VIETNAM, PATH CONTINUED TO SUPPORT THE NATIONAL TB PROGRAM BY ASSESSING PROGRESS ON THE "DOUBLE X" STRATEGY (CHEST X-RAY AND GENEXPERT TEST), SUPPORTING THE APPLICATION OF ARTIFICIAL INTELLIGENCE FOR READING CHEST X-RAYS, AND PERFORMING ANALYSES TO IMPROVE SPECIMEN TRANSPORT SYSTEMS AND DIAGNOSTIC ACCESS. ALSO IN VIETNAM, THE USAID/PATH HEALTHY MARKETS PROJECT INTRODUCED NEW HIV PRODUCTS TO OPTIMIZE CHOICE FOR CLIENTS, SUPPORTED THE DEVELOPMENT OF CRITICAL NEW POLICIES (INCLUDING A FIRST-EVER HIV PRIVATE-SECTOR ENGAGEMENT PLAN), AND RAPIDLY PIVOTED KEY POPULATION PLATFORMS TO DELIVER LIFESAVING COVID-19 AND HIV CARE DURING VIETNAM'S SEVERE FOURTH SURGE OF COVID-19. IN DECEMBER, THE TEAM TRANSITIONED THE PROJECT TO USAID/PATH STEPS, A FIVE-YEAR PEPFAR-FUNDED INITIATIVE THAT BUILDS ON THE ACHIEVEMENTS OF HEALTHY MARKETS. IN PARTNERSHIP WITH THE HEPATITIS FUND, PATH LAUNCHED INTEGRATED AND COMMUNITY-BASED HIV AND VIRAL HEPATITIS SCREENING AT 27 HEALTH FACILITIES IN VIETNAM, TESTING MORE THAN 11,000 PEOPLE FOR HEPATITIS B AND C AND ENROLLING MORE THAN 500 ON TREATMENT. WE ALSO PARTNERED WITH THE MOH TO PROTOTYPE A DIGITALIZED VIRAL HEPATITIS HEALTH INFORMATION AND TRACKING SYSTEM. IN TAJIKISTAN, KAZAKHSTAN, AND UZBEKISTAN, PATH PROVIDED CLINICAL EXPERTISE TO CREATE AND REVISE NATIONAL GUIDELINES AND PROTOCOLS FOR DRUG-SENSITIVE AND DRUG-RESISTANT TB, DEVELOPED PLANS FOR A CLINICAL AUDIT, AND SUPPORTED OPERATIONS RESEARCH AND SCALE-UP PLANNING FOR NEW TB REGIMENS UNDER THE USAID ELIMINATING TB IN CENTRAL ASIA PROJECT. IN UKRAINE, PATH CONTINUED TO LEAD THE USAID-FUNDED SERVING LIFE PROJECT, WHICH REDUCES TB, HIV, AND HEPATITIS C TRANSMISSION IN THE PENAL SYSTEM AND COMMUNITIES ACROSS 12 REGIONS. WE PILOTED INNOVATIVE INTERVENTIONS THAT WILL ULTIMATELY BE TRANSITIONED TO GOVERNMENT LEADERSHIP, INCLUDING MEDICATION-ASSISTED THERAPY, PROVISION OF PSYCHOSOCIAL AND HIV SERVICES FOR PRE-TRIAL DETAINEES, AND INDEX CASE TESTING FOR CONTACTS OF DETAINEES NEWLY DIAGNOSED WITH HIV. PATH CONTINUED TO IMPLEMENT THE USAID-FUNDED SUPPORT TB CONTROL EFFORTS IN UKRAINE (STBCEU) PROJECT, WHICH FOCUSES ON PREVENTION, DETECTION, AND TREATMENT OF TB, DRUG-RESISTANT TB, AND TB/HIV. IN 2021, STBCEU SUCCESSFULLY ADVOCATED FOR THE INTRODUCTION OF STOOL TESTING AS THE PREFERRED METHOD OF TB DIAGNOSIS AMONG CHILDREN, PILOTED MOBILE X-RAY SCREENINGS, IMPROVED ALGORITHMS FOR ACTIVE CASE FINDING AMONG POPULATIONS AT RISK FOR TB, AND PROVIDED TB EDUCATION THROUGH NATIONAL NEWS PROGRAMS. NONCOMMUNICABLE DISEASES PATH IS AT THE FOREFRONT OF EFFORTS TO PREVENT, DETECT, AND TREAT NONCOMMUNICABLE DISEASES (NCDS), INCLUDING DIABETES AND CARDIOVASCULAR DISEASE, IN LOW-RESOURCE SETTINGS WORLDWIDE, WHERE THE BURDEN OF THESE DISEASES IS RISING DISPROPORTIONATELY. IN 2021, PATH CONTINUED TO SERVE AS THE SECRETARIAT OF THE COALITION FOR ACCESS TO NCD MEDICINES AND PRODUCTS. THIS GLOBAL, MULTISECTORAL COLLABORATION WORKS TO INCREASE ACCESS TO NCD MEDICINES AND HEALTH PRODUCTS IN LMICS. IN ADDITION TO GLOBAL ADVOCACY, THE COALITION LED THE DEVELOPMENT AND IMPLEMENTATION OF A FORECASTING PROGRAM FOR NCD MEDICINES AND PRODUCTS IN KENYA AND UGANDA. PATH IMPLEMENTED NCD PROJECTS IN GHANA, KENYA, AND VIETNAM TO BUILD STRONGER PHC SYSTEMS, SUPPLY CHAINS, AND DATA-DRIVEN DECISION-MAKING - ALL CRITICAL COMPONENTS OF HEALTH SYSTEM RESILIENCY. OUR EFFORTS IN GHANA INCLUDED SUPPLY CHAIN STRENGTHENING AND IMPLEMENTATION OF THE NCD NAVIGATOR - A FIRST-OF-ITS-KIND, LOCALLY MANAGED DIGITAL INFORMATION SYSTEM FOR NCD RESOURCE PLANNING AND ALLOCATION - IN 9 OF GHANA'S 16 REGIONS. IN PARTNERSHIP WITH THE GHANA HEALTH SERVICE, PATH'S HEALTHY HEART AFRICA PROJECT, WHICH FOCUSES ON HYPERTENSION MANAGEMENT AT THE COMMUNITY LEVEL, CONDUCTED MORE THAN 500,000 BLOOD PRESSURE SCREENINGS AND LINKED THOSE DIAGNOSED TO TREATMENT. IN SENEGAL, PATH ALSO LAUNCHED THE HEALTHY HEART AFRICA PROJECT, WHILE RWANDA AND TANZANIA PREPARED FOR IMPLEMENTATION. IN KENYA, PATH IMPLEMENTED A CUTTING-EDGE PROGRAM THAT ENABLES COMMUNITY AND HOUSEHOLD SCREENINGS FOR HYPERTENSION, REMOTE BLOOD PRESSURE AND BLOOD SUGAR MONITORING, TELEMEDICINE, COMMUNITY-BASED DRUG DELIVERY, AND ENHANCED DATA MANAGEMENT. WE TRANSITIONED OWNERSHIP OF THE NCD NAVIGATOR TO THE MOH BUT CONTINUED TO PROVIDE TECHNICAL ASSISTANCE. AS THE MOH SEEKS TO IMPROVE THE SUPPLY CHAIN IN PREPARATION FOR UNIVERSAL HEALTH COVERAGE, WE BEGAN IMPLEMENTING SEVERAL INNOVATIONS FOR NCDS, SUCH AS A STOCK TRACKER, AN ELECTRONIC MEDICAL RECORD MODULE, AND LAST-MILE DISTRIBUTION OF NCD MEDICINES AND SUPPLIES. PATH ALSO BEGAN IMPLEMENTING AN HIV/HYPERTENSION INTEGRATION PROJECT IN THREE FACILITIES IN WESTERN KENYA TO INCREASE ACCESS TO CARE. OUR FOCUS IN VIETNAM WAS ON A PHC MODEL THAT USES PUBLIC-PRIVATE PARTNERSHIPS, DIGITAL TOOLS, AND COMMUNITY HEALTH WORKERS TO SUPPORT SCREENINGS AND LINKAGES TO CARE. IN ADDITION, WE CONDUCTED A SUPPLY CHAIN ASSESSMENT TO DETERMINE THE AVAILABILITY AND AFFORDABILITY OF NCD MEDICINES AT THE PHC LEVEL. PATH ALSO LAUNCHED THE DIABETES CAREPAK IN KENYA AND VIETNAM, AN INNOVATIVE SOLUTION TO BUNDLE THE COMMODITIES NEEDED FOR SAFE ADMINISTRATION OF INSULIN AND OTHER DIABETES SELF-CARE PRODUCTS. EXPANSION INTO MALI, MOZAMBIQUE, TANZANIA, AND UGANDA WAS APPROVED TOWARD THE END OF THE YEAR. FINALLY, PATH LED AND CONTRIBUTED TO CONVENINGS TO RAISE AWARENESS OF NCDS AND ORCHESTRATE ACTION TO IMPROVE ACCESS TO NCD PREVENTION AND CARE. |
| FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE: | SEXUAL AND REPRODUCTIVE HEALTH PATH'S WORK IN SEXUAL AND REPRODUCTIVE HEALTH (SRH) IS GUIDED BY THE PRINCIPLES OF CHOICE, EQUITY, AND DIGNITY FOR ALL PEOPLE AND GROUNDED IN AN UNDERSTANDING OF THE COMPLEX SOCIAL, BEHAVIORAL, AND GENDER DIMENSIONS OF SRH THROUGHOUT THE LIFE CYCLE. WE BUILD EVIDENCE AROUND TOOLS AND SERVICES THAT ARE CO-DESIGNED WITH AND FOR WOMEN AND GIRLS TO ADDRESS THEIR DIVERSE NEEDS AND CIRCUMSTANCES, REDUCE BARRIERS, AND EXPAND OPTIONS. PATH IS A LEADER IN THE SELF-CARE MOVEMENT, SUPPORTING INDIVIDUALS AND FAMILIES WHO CHOOSE TO MANAGE THEIR OWN HEALTH. IN SENEGAL, THE MOH, PATH, AND PARTNERS ARE ADVANCING POLICY THROUGH THE SELF-CARE PIONEERS, A COALITION OF CHAMPIONS LEADING THE DEVELOPMENT OF SENEGAL'S SELF-CARE GUIDELINES. THESE WILL BE AMONG THE FIRST NATIONAL SELF-CARE GUIDELINES IN THE WORLD, AND THE FIRST IN FRANCOPHONE AFRICA. WITH ASSISTANCE FROM PATH AND PARTNERS, COUNTRIES HAVE CONTINUED TO ACCELERATE SCALE-UP OF THE CONTRACEPTIVE INNOVATION, SELF-INJECTION WITH SUBCUTANEOUS DMPA (DMPA-SC). LED BY PATH IN PARTNERSHIP WITH JOHN SNOW, INC., THE DMPA-SC ACCESS COLLABORATIVE IN 2021 PROVIDED TECHNICAL ASSISTANCE TO 20 COUNTRIES AND COLLECTED DATA FROM 11 COUNTRIES SHOWING MORE THAN 315,000 CLIENT SELF-INJECTION VISITS. IN UGANDA, PATH AND THE MOH ARE IMPLEMENTING GROUNDBREAKING PERSON-CENTERED PROGRAMS TO DEMONSTRATE HOW SELF-INJECTION CAN BE OFFERED AT SCALE. FOR DECADES, PATH HAS BEEN AT THE FOREFRONT OF EVIDENCE-BASED STRATEGIES TO ADDRESS THE INEQUITABLE BURDEN OF CERVICAL CANCER IN LMICS, FROM HUMAN PAPILLOMAVIRUS (HPV) VACCINE RESEARCH AND DELIVERY TO CERVICAL CANCER SCREENING AND TREATMENT. GLOBALLY, PATH HELPED SHAPE STRATEGIES FOR LMICS AS PART OF WHO'S CALL FOR GLOBAL CERVICAL CANCER ELIMINATION, AND WE CONTINUE TO PURSUE OPPORTUNITIES FOR SECONDARY PREVENTION (I.E., EARLY DETECTION) INTERVENTIONS. IN PERU, PATH IMPLEMENTED A MODEL FOR EARLY DETECTION OF BREAST CANCER APPROPRIATE AND FEASIBLE FOR THESE SETTINGS. WE PARTNERED WITH THE MOH TO DESIGN AND IMPLEMENT A REAL-TIME DIGITAL PATIENT TRACKING SYSTEM FOR BREAST CANCER DETECTION. THROUGH THE USAID IMPROVING MARKET PARTNERSHIPS AND ACCESS TO COMMODITIES TOGETHER PROJECT IN MADAGASCAR, PATH AND PUBLIC- AND PRIVATE-SECTOR CHAMPIONS SUPPORTED THE GOVERNMENT TO DEVELOP A STRATEGY FOR A TOTAL MARKET APPROACH TO IMPROVE ACCESS TO HIGH-QUALITY HEALTH PRODUCTS FOR FAMILY PLANNING (FP), MATERNAL AND CHILD HEALTH, AND MALARIA. IN INDIA, PATH IMPLEMENTED SEVERAL SUPPLY CHAIN STRENGTHENING INITIATIVES TO HELP ENSURE AVAILABILITY OF FP PRODUCTS. WE PILOTED AN INFORMED PUSH MODEL TO REDUCE STOCKOUTS, INTRODUCED KITS FOR LAST-MILE FP AVAILABILITY, DESIGNED A SUPPLY CHAIN MANAGEMENT E-LEARNING COURSE, AND FACILITATED A PARTNERSHIP BETWEEN THE ODISHA STATE GOVERNMENT AND THE INDIA POST FOR FP DELIVERY. WE CONDUCTED A POLICY AND REGULATORY LANDSCAPE FOR PRIVATE-SECTOR FP DELIVERY AND CONTRIBUTED TO INDIA'S FP2030 DRAFT COMMITMENTS ON STRENGTHENING SUPPLY CHAINS. IN MYANMAR, PATH IS FULFILLING THE GROWING NEED FOR INFORMATION AND SERVICES TO ADDRESS GENDER-BASED VIOLENCE (GBV) AND SEXUAL AND REPRODUCTIVE HEALTH AND RIGHTS (SRHR) AMID THE CURRENT LOCAL POLITICAL SITUATION AND COVID-19 PANDEMIC. WITH FUNDING FROM WHO, WE INCREASED GBV AWARENESS IN THE PERI-URBAN YANGON MIGRANT COMMUNITY; SUPPORTED WOMEN IN CRISIS WITH FOOD, SHELTER, AND TRANSPORTATION; CONDUCTED A WELL-BEING WORKSHOP AND WEBINAR; AND FACILITATED A 16-DAY SRHR AND GBV ACTIVISM CAMPAIGN. PATH CONTINUED TO SERVE AS THE SECRETARIAT FOR THE REPRODUCTIVE HEALTH SUPPLIES COALITION, A GLOBAL PARTNERSHIP OF MORE THAN 540 PUBLIC AND PRIVATE ENTITIES AND NONGOVERNMENTAL ORGANIZATIONS WORKING TO EXPAND ACCESS TO CRITICAL SRH AND FP SUPPLIES AND SERVICES. |
| FORM 990, PART III, LINE 4B, DESCRIPTION OF PROGRAM SERVICE: | PATH PUBLISHED SEVERAL ARTICLES ON THE ECONOMIC IMPACT OF RESPIRATORY SYNCYTIAL VIRUS (RSV) AND OTHER ACUTE RESPIRATORY INFECTIONS AMONG INFANTS IN LMICS, AND ON THE IMPORTANCE OF MATERNAL IMMUNIZATION AND THE STRENGTHENING OF RSV ASSAYS. ADDITIONALLY, PATH UPDATED OUR RSV VACCINE AND MONOCLONAL ANTIBODY SNAPSHOT, WHICH PROVIDES AN OVERVIEW OF THE INTERVENTION PRODUCT LANDSCAPE, AND OUR TRIAL TRACKER, WHICH PROVIDES INFORMATION ON RELATED CLINICAL TRIALS. DRUG DEVELOPMENT THROUGH OUR WORK ON DRUG DEVELOPMENT AND INTRODUCTION, PATH HELPS ENSURE THAT PEOPLE AROUND THE WORLD, ESPECIALLY CHILDREN IN LOW-RESOURCE SETTINGS, HAVE RELIABLE ACCESS TO LIFESAVING MEDICINES. OVER THE YEARS, OUR WORK HAS ADVANCED SOLUTIONS FOR A RANGE OF URGENT GLOBAL HEALTH CHALLENGES, INCLUDING ENTERIC AND DIARRHEAL DISEASES, NEGLECTED TROPICAL DISEASES, HIV/AIDS, AND MALARIA. DRAWING ON AN ENDURING COMMITMENT TO HEALTH EQUITY AND A UNIQUE PARTNERSHIP APPROACH THAT SPANS THE ACADEMIC, PRIVATE, NONPROFIT, AND GOVERNMENT SECTORS, OUR WORK OVERTURNS BARRIERS TO HEALTH AT EVERY STAGE OF DRUG DEVELOPMENT AND USE - FROM EARLY RESEARCH TO INTRODUCTION. IN 2021, WE CONTINUED DEVELOPING NEW THERAPEUTICS FOR CRYPTOSPORIDIUM, A DEADLY DIARRHEA-CAUSING PARASITE FOR WHICH NO HIGHLY EFFECTIVE TREATMENT IS AVAILABLE. WE DEMONSTRATED THAT OUR LEAD COMPOUND IS EFFECTIVE IN DAIRY CALVES, A KEY MODEL THAT MIRRORS HUMAN CLINICAL SYMPTOMS. WITH OUR MANUFACTURING PARTNER QUANSYS BIOSCIENCES, WE COMMERCIALLY LAUNCHED THE MICRONUTRIENT AND EED ASSESSMENT TOOL (MEEDAT), A NEW TOOL FOR ASSESSING ENVIRONMENTAL ENTERIC DYSFUNCTION (EED) - AN INTESTINAL DISORDER RESPONSIBLE FOR A SIGNIFICANT PORTION OF THE GROWTH STUNTING OF APPROXIMATELY 140 MILLION CHILDREN WORLDWIDE. MEEDAT WAS USED IN STUDIES OF CHILDREN IN ZAMBIA AND TANZANIA, WITH ADDITIONAL STUDIES PLANNED IN OTHER LOW-RESOURCE SETTINGS. PATH ALSO EXPLORED NEW USES AND PARTNERSHIPS FOR IOWH032, A DRUG CANDIDATE WE PREVIOUSLY DEVELOPED FOR TREATMENT OF CHOLERA, WHICH ALSO HAS POTENTIAL FOR TREATING OTHER DISEASES. |
| FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE: | THROUGH THE IDDS PROJECT, PATH SUPPORTED THE MINISTRY OF AGRICULTURE, ANIMAL INDUSTRIES AND FISHERIES (MAAIF) TO INSTRUCT THE FIRST-EVER ISO/IEC 17025:2017 (THE QUALITY STANDARD FOR OPERATION OF LABORATORIES) TRAINER OF TRAINERS COHORT IN THE COUNTRY AS PART OF A GLOBAL HEALTH SECURITY EFFORT TO IMPROVE DETECTION OF PRIORITY ZOONOTIC DISEASES. WORKING WITH RELEVANT NATIONAL STAKEHOLDERS, PATH DRAFTED AND OPERATIONALIZED A UGANDA STRATEGY FOR COORDINATED AND INTEGRATED SURVEILLANCE OF THESE DISEASES. PATH SUPPORTED THE NATIONAL ANIMAL DISEASES DIAGNOSTICS AND EPIDEMIOLOGY CENTER AND THE ANIMAL HEALTH NATIONAL REFERENCE LABORATORY WITHIN MAAIF TO IMPROVE DATA ENTRY, QUALITY, ANALYSIS, AND REPORTING. ALSO THROUGH IDDS, PATH REVITALIZED FACILITY- AND COMMUNITY-BASED SURVEILLANCE FOR COVID-19 IN EASTERN UGANDA. PATH ALSO SUPPORTED THE DEVELOPMENT OF STANDARD OPERATING PROCEDURES AND WASTE MANAGEMENT GUIDELINES FOR COVID-19 VACCINATION ROLLOUT AND PROVIDED REGULATORY SUPPORT TO THE MOH TO EXPEDITE COVID-19 VACCINE AUTHORIZATION AND SHIPMENT INTO THE COUNTRY. FURTHERMORE IN UGANDA, PATH SUPPORTED COUNTRYWIDE COLD CHAIN EQUIPMENT REPAIR AND MAINTENANCE WHEREBY MORE THAN 100 NONFUNCTIONAL COLD CHAIN DEVICES, SUCH AS VACCINE REFRIGERATORS, WERE REPAIRED. WE EXPANDED THE SCOPE OF THE COLD CHAIN INFORMATION SYSTEM TO INCLUDE COUNTRY-SPECIFIC REQUIREMENTS AND INVENTORY DATA FOR IMPROVED COLD CHAIN EQUIPMENT MANAGEMENT. THROUGH THE UNITAID HIV STAR III INITIATIVE, UGANDA HAS ACHIEVED SIGNIFICANT SCALE-UP IN HIV SELF-TESTING (HIVST) SERVICES. THE COUNTRY IS SET TO DISTRIBUTE 3.5 MILLION HIVST KITS ANNUALLY, MAKING IT THE LARGEST HIVST MARKET GLOBALLY. PATH DEVELOPED THE POST-MARKET SURVEILLANCE NATIONAL PLAN AND STANDARD OPERATING PROCEDURES FOR HIVST. PATH ALSO INTRODUCED TWO WHO-PREQUALIFIED BLOOD-BASED KITS INTO THE COUNTRY TO EXPAND CHOICE AND ACCESS. PATH INTEGRATED THE KITS INTO THE SUPPLY CHAIN AND OTHER SYSTEMS, LEADING TO THE GOVERNMENT'S REVIEW AND ADOPTION OF HIVST TRAINING MATERIALS FOR HEALTH CARE WORKERS AND DEVELOPMENT OF TRAINING MATERIALS FOR PEER HIVST DISTRIBUTORS. ZAMBIA IN PARTNERSHIP WITH THE ZAMBIA GOVERNMENT, PATH SUPPORTED HIGH-QUALITY, CUTTING-EDGE RESEARCH ON PRESSING HEALTH ISSUES, FROM COVID-19 TO MALARIA TO TB. FURTHERMORE, PATH IMPLEMENTED NEW DIGITAL HEALTH TOOLS AND APPROACHES ACROSS THE COUNTRY, FROM OUR PRIVATE-SECTOR PARTNERSHIP "VISUALIZE NO MALARIA" TO THE BETTER IMMUNIZATION DATA INITIATIVE. IN 2021, WE CONTINUED TO SUPPORT THE GOVERNMENT RESPONSE TO THE COVID-19 PANDEMIC. ONE NEW OPPORTUNITY WAS A BAYER-FUNDED PROJECT TO SUPPORT THE MOH ON KEY ASPECTS OF COVID-19 VACCINE ROLLOUT AND DISEASE SURVEILLANCE. ADDITIONALLY, PATH CONTINUED TO PROVIDE TECHNICAL SUPPORT TO THE MOH ON COVID-19 PROTECTIVE MEASURES. IN 2021, THE LIVING LABS PROJECT IN ZAMBIA ENGAGED FRONTLINE IMMUNIZATION HEALTH WORKERS TO IMPROVE VACCINE DELIVERY AND COVERAGE. THROUGH THIS PROJECT, THE WORKERS HELPED ADVISE ON LABELING FOR COVID-19 VACCINES AND HOW TO BEST ACCELERATE VACCINE DISTRIBUTION IN THEIR COMMUNITIES. THEIR FEEDBACK WILL IMPROVE VACCINATION COVERAGE FOR COVID-19 AND BEYOND. OUR WORK IN MALARIA IN ZAMBIA INCLUDED GROUNDBREAKING RESEARCH BY OUR LABORATORY TEAM BASED AT THE NATIONAL MALARIA ELIMINATION CENTER, EVALUATION OF NEW VECTOR-CONTROL TOOLS (SUCH AS THE ATTRACTIVE TARGETED SUGAR BAIT), AND TRAINING OF HEALTH WORKERS ON NEW MALARIA CONTROL GUIDELINES AND PROCEDURES, INCLUDING AT THE COMMUNITY LEVEL. PATH ALSO INCREASED THE NUMBER OF PEOPLE TESTED AND TREATED FOR TB IN ZAMBIA, EXPANDED TB CARE, AND CREATED STRATEGIES TO ADDRESS PEDIATRIC AND DRUG-RESISTANT TB, INCLUDING TRAINING HEALTH WORKERS ON NEW GUIDELINES AND INVESTING IN EFFECTIVE DIAGNOSTICS AT LABORATORIES ACROSS THE COUNTRY. |
| FORM 990, PART VI, SECTION B, LINE 11B | THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE DRAFT WAS SENT TO THE BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE PRINCIPAL FINANCIAL OFFICER SIGNED THE FORM. |
| FORM 990, PART VI, SECTION B, LINE 12C | PATH HAS POLICIES AND PROCEDURES TO ADDRESS CONFLICTS OF INTEREST. PATH MANAGEMENT AND ALL STAFF AT A DESIGNATED LEVEL OR HIGHER WITHIN THE ORGANIZATION MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. PATH ALSO HAS A WELL-DEFINED PROCEDURE FOR IDENTIFYING AND REPORTING ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AMONG BOARD MEMBERS. NEW BOARD MEMBERS ARE ASKED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM WITHIN 30 DAYS OF JOINING THE BOARD AND TO COMPLETE A NEW FORM ANNUALLY THEREAFTER. IN ADDITION, MEMBERS ARE REMINDED TO REPORT ANY NEW ISSUES THAT ARISE OUTSIDE OF THE ANNUAL DISCLOSURE PERIOD. THE DISCLOSURE FORMS ARE REVIEWED BY PATH'S GENERAL COUNSEL, AND IF ANY ACTUAL OR POTENTIAL CONFLICTS ARE IDENTIFIED, GENERAL COUNSEL MAKES A RECOMMENDATION TO THE CHAIR OF THE GOVERNANCE COMMITTEE AND THE CHAIR OF THE BOARD FOR A MANAGEMENT PLAN TO PROPERLY MANAGE ANY CONFLICTS. A FORMAL MANAGEMENT PLAN IS THEN AGREED UPON WITH THE BOARD MEMBER, AND THE ENTIRE BOARD OF DIRECTORS IS INFORMED AT THE NEXT REGULARLY SCHEDULED BOARD MEETING. |
| FORM 990, PART VI, SECTION B, LINE 15 | THE BOARD'S EXECUTIVE COMPENSATION COMMITTEE ANNUALLY REVIEWS SALARIES AND BENEFITS FOR EXECUTIVE EMPLOYEE POSITIONS AND PROVIDES GUIDANCE TO THE PRESIDENT/CHIEF EXECUTIVE OFFICER (CEO) ON COMPENSATION DECISIONS FOR EXECUTIVE POSITIONS. THE COMPENSATION AND BENEFITS FOR PATH'S PRESIDENT/CEO ARE REVIEWED AND APPROVED BY THE ENTIRE BOARD OF DIRECTORS EACH YEAR. PATH ROUTINELY USES THE SERVICES OF EXTERNAL FIRMS TO ASSESS AND BENCHMARK EXECUTIVE COMPENSATION (PRESIDENT/CEO AND DIVISION CHIEFS). THE MOST RECENT MAJOR REVIEW WAS COMPLETED BY THE BOARD COMPENSATION COMMITTEE IN 2021. AT THE REQUEST OF THE BOARD, PATH ENGAGED FUTURE SENSE (A COMPENSATION, BENEFITS, AND HUMAN RESOURCES CONSULTING FIRM) TO REVIEW CURRENT AND PROPOSED BASE SALARIES OF PATH'S PRESIDENT/CEO AND DIVISION CHIEFS. FUTURE SENSE USED DATA FROM MULTIPLE SOURCES TO EVALUATE CURRENT AND PROPOSED BASE SALARIES FOR THESE POSITIONS. THE BOARD'S EXECUTIVE COMPENSATION COMMITTEE REVIEWED THE FUTURE SENSE REPORT AND APPROVED THE USE OF THE REPORT TO ESTABLISH A FRAMEWORK WITHIN WHICH THE PRESIDENT/CEO IS DELEGATED AUTHORITY TO ESTABLISH THE TOTAL COMPENSATION PACKAGES OF THE DIVISION CHIEFS. ADDITIONALLY, FUTURE SENSE REVIEWED THE PROPOSED TOTAL COMPENSATION AND BENEFITS PACKAGE FOR THE PRESIDENT/CEO POSITION AND OBTAINED A SIGNIFICANT NUMBER OF DATA POINTS TO ASCERTAIN ITS REASONABLENESS AND APPROPRIATENESS. THE BOARD APPROVED THE COMMITTEE'S RECOMMENDATION FOR THE PRESIDENT/CEO'S TOTAL COMPENSATION PACKAGE. |
| FORM 990, PART VI, SECTION C, LINE 19 | PATH GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST; MOST DOCUMENTS ARE ALSO AVAILABLE ONLINE. |
Schedule R IRS990ScheduleR
Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (2 entries)
| Address Line1ForeignAddress/AddressLine1Txt | CityForeignAddress/CityNm | CountryForeignAddress/CountryCd | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile Foreign CountryLegalDomicileForeignCountryCd | Exempt Code SectionExemptCodeSectionTxt | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt | Controlled OrganizationControlledOrganizationInd |
|---|---|---|---|---|---|---|---|
| FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND | |||||||
| 207 ROUTE DE FERNEY 1218 LE GRAND-S | GENEVA | SZ | EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH | SZ | 501(C)(3) | PATH | Yes (1) |
| PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH -KENYA | |||||||
| ACS PLAZA 4TH FL LENANA RD PO BOX | NAIROBI | KE | EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH | KE | 501(C)(3) | PATH | Yes (1) |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Annts Rnts Rylts | 0 | ReceiptOfIntAnntsRntsRyltsInd |
| Gift Grnt Or Cap Contri To Oth Org | Yes (1) | GiftGrntOrCapContriToOthOrgInd |
| Gift Grnt Cap Contri From Oth Org | Yes (1) | GiftGrntCapContriFromOthOrgInd |
| Loans Or Guarantees To Other Org | 0 | LoansOrGuaranteesToOtherOrgInd |
| Loans Or Guarantees From Oth Org | 0 | LoansOrGuaranteesFromOthOrgInd |
| Div Related Organization | 0 | DivRelatedOrganizationInd |
| Asset Sale To Other Org | 0 | AssetSaleToOtherOrgInd |
| Asset Purchase From Other Org | 0 | AssetPurchaseFromOtherOrgInd |
| Asset Exchange | 0 | AssetExchangeInd |
| Rental Of Facilities To Oth Org | 0 | RentalOfFacilitiesToOthOrgInd |
| Rental Of Fclts From Oth Org | 0 | RentalOfFcltsFromOthOrgInd |
| Perform Of Services For Oth Org | 0 | PerformOfServicesForOthOrgInd |
| Perform Of Services By Other Org | 0 | PerformOfServicesByOtherOrgInd |
| Sharing Of Facilities | 0 | SharingOfFacilitiesInd |
| Paid Employees Sharing | 0 | PaidEmployeesSharingInd |
| Reimbursement Paid To Other Org | 0 | ReimbursementPaidToOtherOrgInd |
| Reimbursement Paid By Other Org | 0 | ReimbursementPaidByOtherOrgInd |
| Transfer To Other Org | 0 | TransferToOtherOrgInd |
| Transfer From Other Org | 0 | TransferFromOtherOrgInd |
Transactions Related Org TransactionsRelatedOrgGrp (2 entries)
| Transaction TypeTransactionTypeTxt | InvolvedInvolvedAmt | Method Of Amount DeterminationMethodOfAmountDeterminationTxt |
|---|---|---|
| PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH-KENYA | ||
| C | $2,279,943 | FMV |
| FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND | ||
| B | $5,789,794 | FMV |
Comments